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ABSTRACT 
Non-alcoholic steatohepatitis (NASH) is the most severe stage of non-alcoholic 
fatty liver disease (NAFLD) with extensive fibrosis, inflammation and steatosis. To date, 
there are no approved therapies for NAFLD/NASH. To identify novel therapeutic targets 
against hepatic fibrosis, we investigated the role of thrombospondin-I (TSP-1), a protein 
that regulates transforming growth factor beta 1 (TGF-β1) signaling and subsequent 
effects on fibrosis, angiogenesis, and inflammation. We first determined that shRNA-
mediated TSP-1 ablation caused attenuated expression of fibrotic markers in activated 
primary human hepatic stellate cells (HSCs), which are the major myofibroblast 
precursor cells in the liver. To investigate whether TSP-1 has a role in NASH in vivo, we 
examined the effect of TSP-1 genetic deficiency in a mouse model that utilizes a choline-
deficient L-amino acid defined high fat diet (CDAHFD). We demonstrated that 
CDAHFD-fed TSP-1-deficient mice were less prone to hepatic fibrosis, as indicated by 
histology and reduced expression of inflammation and fibrosis mRNA markers. In 
addition, we observed that serum lipid levels were lower in CDAHFD-fed TSP-1-
deficient mice. Transcriptomic analysis of hepatic mRNA from TSP-1 deficient mice fed 
  vi 
control and CDAHFD diets revealed upregulation of the peroxisome proliferator-
activator receptor alpha (PPARα) pathway, which is involved in fatty acid metabolism 
and inflammation in the liver. Published studies indicate that PPARα activation alleviates 
NAFLD/NASH symptoms in mouse models and patients. Our results reveal a previously 
unknown relationship between TSP-1 and PPARα and suggest that TSP-1 could be a 
candidate target for NASH treatment. 
In a second set of studies, we investigated the molecular pathways involved in 
activation of primary human HSCs. We performed transcriptomic analysis of TGF-
β1 activated human HSCs and also characterized the anti-fibrotic mechanisms of the 
bromodomain inhibitor JQ1, which is known to attenuate fibrosis in experimental 
models. Our transcriptomic analysis identified an activated signal transducer and 
activator of transcription 3 (STAT3) signature in TGF-β1-treated HSCs. We determined 
that Cpd188-mediated STAT3 inhibition promotes HSC apoptosis, enabling resolution of 
fibrosis. STAT3 overexpression attenuated Cpd188-mediated apoptosis. Our findings 
highlight an important role for STAT3 in HSC activation. Therefore, STAT3 inhibition 
constitutes a promising direction for hepatic fibrosis treatment. 
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CHAPTER ONE: INTRODUCTION 
Section One: Fibrosis 
 Fibrosis, or pathogenic scarring of the tissue, occurs when normal wound healing 
responses are dysregulated without resolution of injuries. Fibrosis can arise from 
numerous etiologies, from unresolved viral infections, continuous metabolic dysfunction, 
repetitive exposure to toxins and overactive immune system [1]. These etiologies, 
although distinct in nature and characteristics, share common features of pathogenic 
fibrosis: dysregulated production of pro-fibrotic cytokines, growth factors, angiogenic 
factors and proteolytic enzymes that drive the excess deposition of extracellular matrix 
(ECM) composed of collagens, proteoglycans, hyaluronic acids and fibronectins[2]. 
Summarily, these are the features of chronic injury and continuous inflammation as its 
response mechanism. Without proper resolution, tissue homeostasis is disrupted, and the 
parenchyma of the organ is gradually replaced with scar tissues. This loss of tissue 
architecture leads to tissue remodeling, resulting in compromised organ function that 
ultimately leads to organ failure and death.  
 Pathogenic fibrosis is responsible for 45% of morbidity and death in the 
developed world [3]. Some of the key triggers of fibrosis include poorly controlled 
diabetes, cardiovascular disease, high serum cholesterol levels, obesity, hypertension, 
chronic autoimmune diseases, inherited genetic disorders and minor human leukocyte 
antigen mismatches in transplants [4]. These triggers may then evolve into chronic 
fibrotic diseases in various organs such as liver cirrhosis, idiopathic pulmonary fibrosis, 
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chronic kidney disease, and systemic sclerosis that may ultimately progress to organ 
failure and death as an outcome [1].   
 There are core features shared by all fibrotic organs – cell death, metabolic 
dysregulation, myofibroblast differentiation, transforming growth factor beta (TGF-β) 
activation and innate and adaptive immune response to inflammation (Figure 1-1). Cell 
death from tissue injury can result in apoptosis and necrosis that result in an 
inflammatory response. Cell injuries also result in alterations in oxygen nutrient delivery, 
local microperfusion, pH maintenance, and toxin removal [3] . Cells respond to these 
stresses by triggering a multitude of survival and stress responses that are consistently 
activated in chronic fibrosis. Unfolded protein response by endoplasmic reticulum (ER) 
stress and altered mitochondrial function driven by production of excess reactive oxygen 
species (ROS) are two examples of activated stress responses [5]. Activation of TGF-β1, 
a hallmark pro-fibrotic cytokine, signals for myofibroblast differentiation and 
inflammation [6].  In turn, differentiations of various cell types into collagen-producing 
myofibroblasts drive the pathophysiology of fibrosis by production of the scar tissue [7] . 
Finally, all the responses ultimately feed into the inflammation response, driven by both 
innate and adaptive immune response [8]. The inflammation response is critical to 
survival as it eliminates invading or self-generated threats. In a normal wound healing 
process, the pro-inflammatory response of the immune system transition to the pro-
resolution response which then allows for return to the homeostasis. In fibrosis, the 
immune response that guides the wound process is dysregulated, and the pro-
inflammatory response persists without transition to pro-resolution. Persistent 
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inflammation then feeds back into the five other features of fibrosis listed above and the 
incessant cycle of progressive fibrosis ensues.  
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Figure 1-1. Injuries that can lead to fibrosis. 
 EMT: epithelial to mesenchyme transition, ER: endothelium reticulum, ROS: reactive 
oxidative species. Adapted from [5] 
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Inflammation 
 Inflammation is the first line of defense response mounted by the immune system 
when a “danger” signal is detected in the blood stream. When an injury occurs, dead or 
damaged cells (usually structural or parenchymal cell types such as epithelial or 
endothelial cells) release “danger” signals such as pathogen associated molecular patterns 
(PAMPs) and damage associated molecular patterns (DAMPs) [9]. PAMPS and DAMPs 
are then recognized by pattern recognition receptors (PRRs) such as toll-like receptors 
(TLR), nod-like receptors (NLR), retinoic acid inducible gene I (RIG-I)-like receptors, 
lectins and scavenger receptors on resident immune cells such as macrophages or 
dendritic cells [1]. Recognition of these signals then leads to rapid release of cytokines, 
chemokines and growth factors by the resident immune cells that recruit leukocytes, such 
as neutrophils and pro-inflammatory monocytes such as macrophages.  Meanwhile, 
platelet aggregation, clot formation and development of provisional extracellular matrix 
are also initiated at the site of injury. Platelet degranulation also increases blood vessel 
permeability, vasodilation and induction of matrix metalloproteinases (MMPs), which 
allows for efficient recruitment of circulating pro-inflammatory immune cells initiated by 
the resident immune cells.  
Once recruited to the site of injury, the first responder leukocytes such as 
neutrophils and macrophages eliminate cellular debris and dead matter. Simultaneously, 
these cells also amplify the wound healing response by recruiting other inflammatory 
cells such as T cells that will secrete wound-healing cytokines such as transforming 
growth factor beta (TGF-β), platelet-derived growth factor (PDGF) and interleukin-13 
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(IL-13) [2]. These are the initial cascading events of acute inflammation, a critical 
mechanism of the immune system to maintain homeostasis. However, if the injury 
persists, acute inflammation shifts to chronic inflammation, the driving force of 
pathogenic fibrosis. 
Immune cells 
 Innate immune signaling pathways are important drivers of inflammation and 
fibrosis. Effectors of the innate immune response include Cd4+ T cells that secrete and 
respond to pro-inflammatory cytokines associated with fibrosis such as IL-13 and IL-17, 
and monocyte-derived cells such as macrophages and dendritic cells that directly 
influence ECM remodeling and indirectly regulate activated myofibroblasts [3]. The 
importance of IL-13 mediated T cell response has been demonstrated well in 
Schistosomal parasitic infection model of the liver, where IL-13 depletion attenuated 
hepatic fibrosis [10]. Similarly, IL-17 mediated T cell response was critical in the 
bleomycin model of pulmonary fibrosis [11]. Macrophages actively regulate ECM 
modeling by being a primary source of TGF-β1 that activates myofibroblasts, MMPs that 
shape the architecture of the ECM, and TIMPs that regulate the MMPs [12]. 
Transforming Growth Factor Beta I (TGF-β1) 
TGF-β1 is a pleiotropic cytokine involved in maintaining homeostasis in 
numerous biological functions such as embryogenesis, immunity, carcinogenesis, cell 
proliferation and migration, wound healing, inflammation and fibrosis [13]. In the context 
of pathogenic fibrosis, TGF-β1 is a well-established driver of the disease; TGF-β1 
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activates differentiation of various cell types into collagen-producing myofibroblasts and 
also recruits immune cells to the site of injury. Indeed, increased TGF-β1 expression 
correlate with increased disease severity [14-16]. TGF-β1 is primarily regulated by 
secretion and activation of latent TGF-β1 by dissociation of TGF-β1 from latency-
associated protein (LAP) that is catalyzed by numerous agents, such as cathepsins, 
plasmin, calpain, thrombospondins, integrins and matrix metalloproteinases [17-19]. 
Once activated, TGF-β1 signals through its canonical SMAD (homologues of the 
Drosophila protein mothers against decapentaplegic Mad and the Caenorhabditis elegans 
protein Sma) signaling pathway where its cognate receptors trigger signaling by SMAD 
family of transcription factors to initiate many pro-fibrotic target genes such as collagens 
and fibronectins that constitute the scar tissue. TGF-β1 also signals through multiple non-
canonical pathways independent of SMAD, such as tumor necrosis factor (TNF) receptor 
associated factor 4 (TRAF4), TGFβ activated kinase 1 (TAK1), p38 mitogen-activated 
protein kinase (p38 MAPK), Rho, phosphoinositide 3 kinase (PI3K), AKT, extracellular 
signal regulated kinase (ERK) and nuclear factor-кB (NF-кB) [20]. Furthermore, TGFβ 
signaling can also be influenced by different signaling pathways, including Wnt, 
Hedgehog, Notch, interferon (IFN) and Ras pathways. Therefore, TGFβ signaling is a 
complex pathway with numerous cross talks that allows for various context-dependent 
functions in multitude of cellular processes. 
Myofibroblasts 
Myofibroblasts are the primary source of excess extracellular matrix (ECM) that 
constitutes the scar tissue. Myofibroblasts are contractile cells that are characterized by 
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increased expression of cytoskeletal protein alpha smooth muscle actin (α-SMA) and 
prolific production of excess extracellular matrix (ECM) components including type I 
collagen and fibronectin that constitute the scar tissue [21]. Expression of α-SMA in 
myofibroblasts allows formation of stress fibers that confers contractility to promote 
wound closure, where edges of the wound are pulled toward each other. At the site of the 
wound, they produce ECM matter to form the scar tissue to close the wound that is 
critical in the healing process. 
 In addition to its role in generating excess ECM for the scar, myofibroblasts also 
secrete angiogenic factors such as vascular endothelial growth factor (VEGF) and 
angiopoietin that recruit peripheral epithelial and endothelial cells to form new blood 
vessels and ECM that promote further healing to re-establish normal function 
homeostasis [22, 23]. Myofibroblasts also produce pro-inflammatory cytokines and 
chemokines such as TNF-α, monocyte chemoattractant protein 1 (MCP-1), and TGF- β1 
that recruit immune cells to the site of injury and promote the inflammatory response and 
subsequent repair [1]. However, in progressive fibrosis, this wound healing repair process 
is dysregulated with consistent non-resolved inflammation. Unresolved inflammation 
results in continuous infiltration of immune cells and persistent pro-inflammatory signals 
promote continuous proliferation of myofibroblasts and production of excess ECM that 
forms the scar tissue.  
Fibrotic ECM deposition differs from normal scar tissue in quantity and 
composition. Prolonged and chronic inflammation results in changes in the ECM 
composition to mainly fibrillar, tightly packed and cross-linked collagens that are 
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resistant to degradation by metalloproteases (MMPs) [24]. In addition, a pro-fibrogenic 
environment also contains overexpression of MMP inhibitors, tissue inhibitors of 
metalloproteinases (TIMPs) [25, 26]. Ultimately, uncontrolled fibrosis progression will 
result in eventual replacement of the parenchyma by scar tissue, resulting in organ failure 
and death.  Therefore, myofibroblasts are critical orchestrators of the wound-healing 
immune process that also serve as key pathogenic effector and modulator cells in fibrosis.   
As the definitive effector cell in fibrosis, myofibroblasts’ origins and factors that 
lead to trans-differentiation, proliferation and apoptosis have been extensively examined. 
Myofibroblasts can be derived from numerous cell types: epithelial cells, leukocytes, 
endothelial cells and pericytes [1]. Pericytes are mesenchymal cells on the abluminal side 
of the endothelial cells lining the capillaries that play a critical role in development, 
regulation and maintenance of microvasculature. Pericytes can also transition into 
myofibroblasts, a process that is critical in development of fibrosis.  Epithelial cells can 
also undergo epithelial cell to mesenchymal transition (EMT), a process often involved in 
embryogenesis, to acquire myofibroblast-like characteristics [7]. Circulating fibrocytes of 
leukocyte progeny can serve as a source of myofibroblasts. Endothelial cells have also 
been observed to transition into myofibroblasts (EndoMT) [27]. However, in pathological 
fibrosis of numerous organs including kidney, liver and heart, most of the scar-forming 
ECM is produced by pericyte-derived myofibroblasts [28, 29], which underscores the 
importance of pericyte to myofibroblast transition.  
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Resolution 
 Recent clinical observations of fibrosis regression, particular in the liver, 
demonstrates that fibrosis is a dynamic and bi-directional process that can be resolved to 
return to homeostasis [30]. There are several conditions that set up the switch from a pro-
fibrotic environment to a pro-resolution environment. In order to break down the 
accumulated scar tissue, the balance of TIMPS to MMPs must favor MMPs to increase 
protease activities that break down the accumulation of ECM. Pro-resolution 
macrophages are also essential for fibrosis resolution, as demonstrated by depletion of 
macrophages during a recovery phase in a bleomycin model of lung fibrosis and liver 
injury that led to prevention of fibrosis resolution [31, 32] .  Myofibroblast apoptosis [33] 
or reversion to quiescence [34] has also been noted as key features in recovery after 
cessation of injury in liver model of fibrosis.  Better understanding of fibrosis resolution 
may allow for development of therapeutics to induce pro-resolution pathways to guide 
fibrotic responses from progression to resolution.  
Section Two: Hepatic Fibrosis 
The liver is the largest internal organ in the human body and serves numerous 
essential functions such as: detoxification of xenotoxic agents and metabolites; protein 
synthesis; uptake, storage and biotransformation of amino acids, carbohydrates, lipids 
and vitamins; and hormone synthesis. Liver fibrosis is a major cause of mortality 
worldwide [35]. Fibrotic liver is characterized by excess extracellular matrix build up, 
loss of parenchymal cells and inflammation fueled by infiltrating immune cells. 
Progressive unresolved scarring of the liver can result from numerous etiologies such as 
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hepatitis B and hepatitis C viral infection, metabolic imbalance such as insulin resistance 
and exposure to toxins such as excess alcohol consumption [36]. Pathogenic buildup of 
the scar tissue that progressively replaces liver parenchyma leads to tissue remolding, 
loss of vascular structure, and impairment of organ function that may ultimately lead to 
cirrhosis, hepatic carcinoma and death.  
The liver has remarkable regenerative abilities and can recover rapidly from acute 
injuries even with large loss of mass [36]. Wound healing response is normally beneficial 
and critical to the homeostasis of the liver; however, if the injuries are chronic and remain 
unresolved, the healing response becomes de-regulated and pathogenic. The plasticity of 
liver’s ability to regain homeostasis from fibrotic, even bordering on cirrhotic, to fully 
recovered state with complete dissolution of scar tissue has been demonstrated in 
numerous patients by recent remarkable advancements in direct anti-fibrotic therapies 
targeting the cause of chronic injury, such as irradiation of hepatitis C virus infection or 
suppression of hepatitis B viral replication [37, 38]. Hence, liver fibrosis is a dynamic 
process with progression that can be stopped with promotion of resolution. However, 
molecular mechanisms underlying many fibrotic diseases in the liver are not yet clearly 
understood. For example, the exact cause and the mechanism behind progression from 
non-pathogenic fatty liver to chronically inflamed and progressively fibrotic non-
alcoholic steatohepatitis (NASH) is not well understood although many studies are 
underway [39].  
With these limitations in current understanding of numerous etiological 
pathogenesis of liver fibrosis, current available therapy for liver fibrosis or cirrhosis is 
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liver transplantation. Furthermore, liver fibrosis dramatically increases the risk of 
hepatocellular carcinoma (HCC) [40]. Therefore, better understanding of molecular 
events and fundamental mechanisms in hepatic fibrosis is critical and urgently needed to 
develop novel treatments. Therefore, rigorous efforts in target identification and 
validation in vitro and in vivo animal models are essential in developing successful 
clinical anti-fibrotic therapies.  
Hepatic fibrosis is a complex and dynamic process involving multiple cross talks 
amongst the parenchymal, mesenchymal and infiltrating immune cells after injury. There 
are four resident cell types in the liver: hepatocytes, Kupffer cells, hepatic endothelial 
cells and hepatic stellate cells (Figure 1-2). Hepatocytes are the parenchymal and most 
abundant cells of the liver. Kupffer cells are resident macrophages and hepatic 
endothelial cells form the fenestration in the space of Disse. Hepatic stellate cells are 
pericytes on the abluminal side of hepatic endothelial cells that are normally quiescent.  
However, once the liver is injured, the hepatic stellate cells are activated and differentiate 
into rapid proliferating myofibroblasts that produce ECM to aid in wound healing [41].  
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Figure 1-2. Key hepatic cell types under normal and injured state. 
 Adapted from [8] 
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In the liver, hepatic stellate cell (HSC) derived myofibroblasts are also the main 
contributor of pathogenic fibrosis from de-regulated wound healing process [41]. The 
importance of hepatic stellate cells in hepatic fibrosis has been demonstrated by 
numerous animal model studies with HSC specific ablation that significantly reduced 
fibrotic lesions [29, 42]. Therefore, activation of HSC and consequent differentiation into 
myofibroblasts is a critical initiating event in the development of hepatic fibrosis. 
However, in-depth knowledge of critical pathways and mechanisms that can modulate 
HSC activation for therapeutic benefit is still in early development. 
Fibrosis of the liver is initiated in multiple stages (Figure 1-3). First, injury from 
various sources such as toxin ingestion, viral or parasitic infection, metabolic stress or 
autoimmune dysfunction, leads to death of hepatocytes, the parenchymal and most 
abundant cells in the liver. Deaths of hepatocytes, regardless of its form as apoptosis, 
necrosis or necroptosis, are sensed by resident immune cells of the liver, Kupffer cells, by 
the release of various signals released by dying cells and cell debris [43]. Kupffer cells 
are then activated to release numerous pro-inflammatory and pro-fibrotic mediators such 
as TGFβ-1, MCP-1 and TNFα [4]. The injury and the release of pro-inflammatory signals 
also trigger sinusoidal endothelial cells in the liver to lose the characteristic fenestration, 
which result in increased pressure in the hepatic sinusoid [44]. These mediators also 
activate hepatic stellate cells (HSCs) into myofibroblasts that rapidly proliferates and 
produce excess ECM. Furthermore, activated HSCs gain contractility, and increased 
stiffness from scar tissue further exacerbates the increasing sinusoidal pressure.  
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Figure 1-3. Diagram of normal liver homeostatic wound healing process and 
pathogenic fibrosis.  
Adapted from [45] 
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Non-Alcoholic Fatty Liver Disease 
Non-alcoholic fatty liver disease (NAFLD) is a term that describes a spectrum of 
liver conditions that are accompanied by fatty liver. The initial stage, fatty liver, or 
hepatic steatosis, is referred to as NAFL (non-alcoholic fatty liver). The end stage of 
NAFLD is non-alcoholic steatohepatitis (NASH), where NAFL has progressed 
significantly to develop extensive hepatic steatosis, inflammation, hepatocyte ballooning 
and damage, and fibrosis. Up to 25% of NAFLD patients progress to NASH [46]. The 
factors that lead NAFLD to NASH progression are currently unknown. 
 Left untreated, NASH patients may progress to liver cirrhosis and/or 
hepatocellular carcinoma, and death. Steatohepatitis is the strongest indicator of fibrotic 
development as its presence correlates strongly with fibrosis severity [47]. There is no 
current therapy available to treat NAFLD/NASH, although numerous clinical trials are 
currently underway [39]. NASH typically occurs in the setting of metabolic syndromes, 
such as obesity, type 2 diabetes, systemic hypertension, and dyslipidemia [39]. However, 
there are also sizeable percentages of patients who are not obese [48], which 
demonstrates the complexities and heterogeneity behind mechanisms that cause the onset 
and progression of the disease. Nevertheless, the presence of metabolic syndromes is the 
strongest risk factor for NAFLD/NASH. The association of NAFLD and metabolic 
syndromes may be bi-directional, meaning metabolic disease may increase NAFLD risk 
but NAFLD also increase co-morbidities of metabolic syndromes. Thus, effective 
treatment of NASH could benefit features of metabolic syndrome and vice versa. For 
example, bariatric surgery in obese patients results in improvements in metabolic 
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syndrome-associated symptoms such as NAFLD/NASH, cardiovascular events and renal 
complication [49, 50].  With a rising epidemic of metabolic syndrome in the developed 
world, NASH is forecasted to be the leading cause of liver transplantation by 2020 in the 
United States [51].  
Some genetic factors have been identified to be protective or increase 
susceptibility to development of NASH. Single nucleotide polymorphism in patatin-like 
phospholipase domain containing 3 (PNPLA3) gene has been linked to higher risk of 
NASH [52]. The PNPLA3 gene regulates lipolysis of hepatocyte lipid droplets. Patients 
with the risk polymorphism have PNPLA3 proteins that accumulate on lipid droplets and 
are resistant to normal proteasomal degradation, thereby impeding lipolysis. Interestingly, 
the risk in patients with PNPLA3 polymorphism was highest in coexistence with 
adiposity, illustrating that both genetic and environmental causes drive the disease [53]. 
Recent genome wide association study (GWAS) revealed a splice variant in HSD17B13 
gene that was protective in patients with fatty liver [54]. The splice variant yields a 
truncated and non-functional protein, suggesting that normal HSD17B13 somehow 
promotes hepatocellular damage. Indeed, reduced HSD17B13 protein lowers levels of 
serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) that implies 
attenuated hepatocyte injury. These genetic factors reveal some of the pathways and 
mechanisms that may be modulated to successfully attenuate NAFLD/NASH. 
 
  
18 
Lipid metabolism and mitochondrial dysfunction in NAFLD 
Hepatic steatosis is a sign of imbalance between lipid availability and removal. 
Lipids are made available from circulating lipid uptake or de novo lipogenesis. Available 
lipids can then be catabolized or removed via free fatty acid oxidation or triglyceride rich 
lipoprotein secretion. Excess fat accumulates in the liver when lipid availability exceeds 
catabolism and removal. Ultimately, excess fat around the liver results in oxidative stress 
and injury, inflammation and fibrosis. One model of NAFLD suggests a “two-hit” 
hypothesis with first hit comprising of initial metabolic stress, such as fatty liver and/or 
insulin resistance and a second hit arising from various causes such as oxidative stress, 
mitochondrial dysregulation and infiltration of pro-inflammatory cytokines [55].  Another 
more recent hypothesis suggests a substrate-overload model of liver injury and NASH 
where NASH develops when the liver’s capacity to handle metabolic energy substrates is 
overwhelmed as toxic lipid metabolites accumulate, inducing hepatocellular stress, 
injury, and death, that leads to fibrosis (Figure 1-4). Nevertheless, both hypotheses 
emphasize the role of excess fat availability in the liver.  
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Figure 1-4. Liver injury model of NAFLD/NASH. 
 Adapted from [39] 
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The liver plays an essential role in lipid metabolism. In the process of lipid 
metabolism, the liver is responsible for liposynthesis, de novo lipogenesis, fatty acid beta 
oxidation, lipolysis, lipoprotein synthesis and lipid export.  Hepatic free fatty acids can be 
derived from dietary triglycerides, de novo synthesis in the liver, lipolysis of adipose 
tissue, decreased lipid export and reduced oxidation of fatty acids [56]. The primary 
sources of fatty acids in the liver are from lipolysis of triglyceride in adipose tissue that is 
regulated by insulin on adipocytes. Increased fatty acids from lipolysis may arise from 
two conditions: metabolic stress and inflammation.  Under metabolic stress with insulin 
resistance, impaired insulin signaling in adipose tissue leads to dysregulated lipolysis and 
excess delivery of fatty acid to the liver. [57].  
 Another major source of fatty acids is via de novo lipogenesis (DNL) from 
glucose and fructose. Stable isotope study that traced the source of hepatic lipids revealed 
that large proportions of hepatic lipids in NAFLD patients are derived from de novo 
lipogenesis [58]. Key regulators in DNL are steroyl-CoA response element binding 
protein-1c (SREBP-1c), a transcriptional regulator of DNL enzymes, and nuclear 
farnesoid X receptor (FXR), a nuclear transcription factor that regulates the expression of 
enzymes in the DNL pathway [39].  
Fatty acids in the liver are then metabolized via mitochondrial beta oxidation to 
generate ATP or via esterification to form triglycerides that are then exported to the blood 
as very low density lipoprotein (VLDL). Triglycerides that are not exported form lipid 
droplets in hepatocytes, a key feature in NAFLD. Hepatocytes are rich in mitochondria; 
mitochondria constitute 18% of the liver cell volume [56]. Hepatic mitochondria are the 
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primary sites of fatty acid oxidation. Mitochondrial beta oxidation catabolizes fatty acids 
to generate acetyl CoA, which then enters tricarboxylic acid cycle (TCA cycle, Krebs 
cycle) to generate ATP, as well as reactive oxygen species (ROS).  Therefore, increased 
fatty acid availability in the liver will lead to increased ROS production which then 
results in increased DNA and protein damage and inflammation. 
 Mitochondrial dysfunction has been shown to be closely related to the 
pathogenesis of NAFLD [59]. NAFLD patients and animal models with NASH are 
observed to display signs of hepatic mitochondrial dysfunction such as ultrastructural 
lesions, depletion of mitochondrial DNA, decreased activity of respiratory chain 
complexes and impaired mitochondrial β-oxidation [60, 61]. These mitochondrial 
dysfunctions may be due to excess reactive oxygen species, increased inflammation and 
altered activities of nuclear receptors such as PPARs that regulate glycolytic and 
oxidative mechanisms. [56]. However, it not yet understood whether mitochondrial 
dysfunction is the cause of NAFLD pathogenesis or whether it is a consequence of 
NAFLD pathogenesis.  
 Monitoring mitochondrial dysfunction may be a useful non-invasive biomarker 
for diagnosis and/or prognosis in NAFLD. One sign of mitochondrial dysfunction in the 
liver is perturbation in amino acid metabolism. The liver is a primary orchestrator of 
nitrogen metabolism in the body. The liver eliminates the potentially toxic nitrogen of 
amino acids via numerous reactions, including transamination, deamination and urea 
formation. The by-products of amino acid metabolism are conserved as carbohydrate via 
gluconeogenesis or as fatty acid via fatty acid synthesis.  Altered amino acid metabolism 
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has been associated with NAFLD where NAFLD patients were observed to have 
increased serum branched-chain amino acids (BCAA) concentrations [62]. Furthermore, 
plasma free amino acid profiles (ratio of BCAA to aromatic amino acids) of generally 
healthy subjects with previously undiagnosed NAFLD were predictive of NAFLD and its 
progressive state [63-65].  
Inflammation in NAFLD/NASH 
Liver fat accumulation in NAFLD/NASH is associated with increased lipotoxicity 
from overabundance of free fatty acids, free cholesterol and other toxic lipid metabolites. 
In NAFLD, lipotoxicity, mitochondrial dysfunction, oxidative stress, increased ROS and 
endoplasmic reticulum (ER) stress from hepatocytes contribute to activation of 
inflammatory pathways (Figure 1-5). Increased expression of pro-inflammatory cytokine 
tumor necrosis factor alpha (TNF-α) and IL-6 from adipocytes also contributes to 
activation of inflammatory pathways in NAFLD [57]. Insulin resistance, a key risk factor 
in NAFLD, is also closely associated with inflammation, since chronic inflammation is a 
hallmark component of insulin resistance pathogenesis [66]. Depletion of Kupffer cells, 
the resident macrophage of the liver, also prevents diet-induced steatosis and insulin 
resistance. Not surprisingly, chronic inflammation has been suggested to be the 
connection between insulin resistance and development of NALFD. Inflammation of the 
liver marked by increased immune cell infiltration and damaged hepatocytes are key 
markers of NALFD progression and disease severity that eventually leads to fibrosis. 
Therefore, attenuation of the inflammatory response may be a key pathway in NAFLD to 
treat and prevent progression to NASH.  
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Figure 1-5. Diagram showing impact of increased fatty acid in NAFLD 
development.  
Increased fatty acid in the liver promotes mitochondrial dysfunction, inflammation and 
fibrosis. FA: Fatty acid,  ROS: reactive oxygen species, PKC: protein kinase, CJNK-IRS: 
c-Jun N-terminal kinase insulin receptor substrate, PP2A: Protein phosphatase A. 
Adapted from [67]  
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 In vivo models of hepatic fibrosis in NASH 
There are multiple methods of inducing hepatic fibrosis in murine models such as 
carbon tetrachloride (CCl4), bile duct ligation (BDL), alcohol, and diet-induced hepatic 
fibrosis. The models represent different etiology and pathology of hepatic fibrosis 
development. For example, carbon tetrachloride models acute injury, BDL models 
cholangiohepatitis, helminth infection models parasitic infection, and high fat 
diet/methionine deficiency models metabolic dysfunction to recapitulate the liver in 
context of the disease of interest. Choline deficient L amino acid defined high fat diet 
(CDAHFD) is a recently reported method of modeling human NASH in mice [68]. 
Methionine and choline are necessary for the secretion of very low density lipoproteins 
(VLDL) type of triglyceride from the liver, and a diet deficient in both will result in 
impaired lipid export. Mice fed a diet completely deficient in methionine and choline 
present with steatosis (excess fat in liver), hepatocellular death, oxidative stress and 
fibrosis, similar to the phenotype of human NASH [69]. However, the mice also show 
massive weight loss due to loss of skeletal muscle and visceral fat leading to frequent 
early death [70] which could be problematic with  long- term experiments typical of diet 
induced fibrosis in mice. CDAHFD overcomes the systemic weight loss by addition of 
0.1% methionine to the choline-deficient diet, and addition of high fat (60 kcal% fat) to 
the diet reduces the time to develop fibrosis from 20 weeks without high fat to 14 weeks 
in mice [68].  
 
  
25 
Strategies to identify anti-fibrotic targets in hepatic fibrosis/NAFLD 
TGF-β1, a hallmark pro-fibrotic cytokine, has been a target of interest for fibrotic 
diseases such as systemic sclerosis, focal segmental glomerulosclerosis and idiopathic 
pulmonary fibrosis. Various approaches such as anti-sense oligonucleotides, ligand traps, 
antibodies, and small molecule inhibitors have been explored in clinical trials [20]. 
However, despite its key role in fibrosis, directly targeting TGF-β1, as an anti-fibrotic 
approach may not be an ideal option, or a simple approach, due to its pleotropic roles in 
immune regulation and carcinogenesis. Interestingly, the anti- TGF-β1 agent 
metelimumab, a humanized antibody against TGF-β1, did not demonstrate anti-fibrotic 
efficacy in clinical trials with scleroderma (SSc) patients [20]. Furthermore, TGF-β1  
deficient mice have multiple autoimmune diseases and are prone to carcinogenesis [3]. 
Therefore, the consequences of direct TGF-β1 antagonism regarding therapeutic benefit 
to possible safety risk must be carefully explored and evaluated. Instead, approaches to 
modulate TGF-β1 mediated fibrosis by targeting other modulators in fibrotic 
pathogenesis may be better viable prospects. For example, pirfenidone, the only approved 
therapy for idiopathic pulmonary fibrosis, acts on an unidentified target that ultimately 
results in attenuation of TGF-β1 mediated fibrosis [71]. Here we describe various 
possible anti-fibrotic targets that have been associated with fibrotic pathogenesis and/or 
NASH. 
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Thrombospondin-I (TSP-1) 
One of the key regulators of TGF-β1 activity is thrombospondin-I (TSP-1), a 
large 450 kDa homo-trimeric glycoprotein with multiple functional domains. TSP-1 
consists of three polypeptide chains connected by multiple disulfide bonds. There are six 
distinct domains with various functions in each monomer- the amino (N) terminal 
domain, procollagen region, Type I repeats, Type II repeats, Type III repeats and 
carboxyl (C)-terminal domain.  The N terminal domain is responsible for degradation and 
internalization of TSP-1 via its heparin binding domain and also plays a role in cell 
adhesion and chemotaxis by interacting with various integrins and calreticulin. The C 
terminal domain plays a role in cell adhesion, migration, platelet accumulation and nitric 
oxide signaling regulation by interaction with CD47 and integrins. The procollagen 
domain is involved in suppression of angiogenesis and the three repeats (Type I, II, III) 
play various roles in cellular adhesion, migration, growth and angiogenesis by numerous 
interaction partners including latent TGF-β1 and CD36 by Type I repeats. 
 TSP-1 is expressed by many types of cells including platelets, hepatocytes, 
stellate cells, megakaryocytes, vascular smooth muscle cells, fibroblasts, endothelial 
cells, epithelial cells and keratinocytes [72]. TSP-1 is usually expressed at very low levels 
under physiological conditions but can be upregulated in injurious or pathophysiological 
environment. Once expression is induced, TSP-1 is secreted to the extracellular matrix 
where it can interact with numerous partner proteins such as receptors, growth factors, 
proteases, cytokines and various structural components of the extracellular matrix [73]. 
The role of TSP-1 can vary widely depending on its interaction partner.  
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One of TSP-1’s well-known functions is to activate latent TGF-β1. Specifically, 
short linear peptide sequence Lys-Arg-Phe-Lys (KRFK) in TSP-1 binds to the Leu-Ser-
Lys-Leu (LSKL) motif in the latent associated peptide (LAP) of TGF-β1, resulting in 
disengagement of LAP from TGF-β1 for consequent TGF-β1 activation [74, 75]. Mice 
with homozygous TSP-1 mutation compared to TGF-β1 display similar but less extreme 
phenotypes, including multiple organ inflammation and epithelial hyperplasia [76]. In 
addition to TGF-β1 activation, TSP-1 is also important in numerous cellular functions 
such as angiogenesis, inflammation, cellular adhesion, migration, and growth. TSP-1 
interacts with a variety of proteins including its membrane bound receptors CD36, CD47 
and other proteins of the extracellular matrix such as matrix metalloproteinases and 
integrins to fulfill its many functions in a cell and context dependent nature [73]. TSP-1 
also plays a critical role in ECM homeostasis by directly impacting collagen fibril 
formation by interacting with collagen, lysyl oxidase precursors and collagen cross 
linking sites[77]. 
TSP-1 expression is increased in various human fibrotic diseases.  In the liver, 
TSP-1 gene THBS1 is a typical signature of cirrhosis resulting from alcoholic fibrosis, 
non-alcoholic steatohepatitis (NASH) and congenital hepatic fibrosis [78, 79]. Similar 
gene expression results are also observed in mouse models of liver diseases including 
diet-induced cholestatic hepatic injury via 3, 5-diethoxycarbonyl-1, 4-dihydrocollidine 
(DDC) administration and hepatotoxic post-necrotic liver fibrosis by carbon tetrachloride 
(CCl4) [78]. Competitive antagonist peptide (LSKL) targeting TSP-1’s interaction site 
with latent TGF-β1 also attenuates fibrosis in mouse model of toxin induced liver fibrosis 
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[80] and subarachnoid fibrosis [81]. TSP-1 deficiency in mice has also been observed to 
be protective against fibrosis in numerous organs such high fat diet induced muscle [82] 
and renal fibrosis [83].  LSKL peptide administration immediately after injury also 
accelerated liver regeneration in mice following partial hepatectomy, suggesting that 
TSP-1 mediated activation of TGF-β1 also plays a role in not only fibrosis but liver 
regeneration [84].  
 In addition to being highly expressed in fibrotic tissues, TSP-1 is also highly 
expressed in diabetic and obese subjects such as in adipose tissues in rodent models of 
obesity and in obese human patients [85, 86]. TSP-1 expression in visceral adipose tissue 
was strongly associated with obesity, insulin resistance and inflammation in human obese 
patients [86]. Increased expression of TSP-1 may be due to increased expression of TGF-
β1 in obese adipose tissues[87]. In a mouse model of high fat diet induced obesity, TSP-1 
also regulated adiposity and metabolic dysfunction by enhancing adipose inflammation 
and adipocyte proliferation [88]. TSP-1 has been implicated in numerous manifestations 
of organ dysfunction in diabetes and obesity, such as diabetic cardiomyopathy, diabetic 
nephropathy and β- cell function in the pancreas. However, the role of TSP-1 in 
NAFLD/NASH has not yet been explored.  (CLARIFY WHAT HASEN”T BEEN 
STUDIED) 
Peroxisome proliferator activated receptors (PPAR) 
Recently, peroxisome proliferator activator receptors (PPARs) have been 
identified as a target of interest for NASH. PPARs are ligand-activated nuclear receptors 
that are highly expressed in the liver where they control insulin sensitivity, glucose and 
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lipid metabolism and inflammation. PPARα is an isoform that is highly expressed in 
hepatocytes that regulates genes involved in fatty acid transport, beta oxidation and the 
inflammatory response. PPARγ is an isoform highly expressed in adipose tissues that 
promotes differentiation of adipocytes, glucose uptake and triglyceride storage to reduce 
free fatty acid availability. Decreased expression of PPARα has been correlated with 
increasing severity of NASH [89]. Furthermore, PPARα agonists have been demonstrated 
to show improvements in liver histology but not fibrosis in human patients [90].  PPARγ 
has also been demonstrated to play a role in maintenance of HSC quiescence [91]. 
Various PPAR agonists with different specificities toward the isoforms have been 
demonstrated to have beneficial effects in preclinical models of NASH and in patients 
[90].  Therefore, numerous clinical trials are underway to identify various modulators of 
PPAR activity for NASH treatment [39].  
Signal transducer and activator of transcription 3 (STAT3) 
 Activation of Signal transducer and activator of transcription 3 (STAT3) has 
recently been identified as an event that integrates numerous pro-fibrotic pathways to 
ultimately promote tissue fibrosis [92]. STAT3 is a pro-inflammatory transcription factor 
involved in cell survival, proliferation and differentiation in various cell types including 
embryonic stem cells, monocytes, B lymphocytes, hepatoma cells, hepatocytes, and 
cancer stem cells [93]. It is activated by numerous cytokines and growth factors, 
including the IL-6 family of cytokines, IL-10, leptin and IL-22. In the liver, hepatocytes 
express high levels of gp130, a common membrane receptor for the IL-6 family of 
cytokines that signals through STAT3. STAT3 signaling in hepatocytes is involved in the 
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acute phase response, and liver regeneration [94]. STAT3 signaling pathway also plays a 
key role in the survival and proliferation of HSCs, a key source of ECM-producing 
myofibroblasts in fibrosis [95-97]. STAT3 activity is detected in numerous models of 
liver injury and in hepatic biopsies from patients with liver diseases [92, 96, 98]. Recent 
studies have also shown that STAT3 plays a key role in myofibroblast activation in 
models of fibrosis in numerous organs including liver, lung and skin [92, 96]. Although 
the role of STAT3 has not been examined in the context of NASH, STAT3 may be an 
important target to address inflammation-driven hepatic fibrosis.   
Section Four: Summary and Specific Aims 
 Liver fibrosis is a serious medical burden worldwide. Specifically, in NASH, 
identification of critical modulators that drive the pathophysiology of the disease may 
lead to development of novel NASH-specific therapeutics where none is currently 
available. In addition, the activation of hepatic stellate cells to myofibroblast transition is 
a common pathway in development of numerous forms of hepatic fibrosis. Therefore, 
identifying targets that halt HSC activation and transition to myofibroblasts may be an 
attractive therapeutic target to address hepatic fibrogenesis in general. TSP-1 has been 
associated with metabolic syndrome mediated fibrosis of the kidney, muscle and heart, 
but whether it plays a role in NAFLD/NASH has not been explored. TSP-1 activates 
several signaling pathways that contribute to development of NAFLD/NASH including 
activation of latent TGFβ-1 to induce fibrogenesis and also by interacting with its 
receptor, CD36, to regulate lipid metabolism. Therefore, we hypothesized that inhibition 
of TSP-1 may be a pathway of interest in NAFLD/NASH. In addition, we hypothesized 
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that defining the key events in activation and anti-fibrotic inhibition of activation of 
primary human HSCs may allow identification of pathways critical in hepatic fibrosis. 
We tested these hypotheses by completing the following specific aims. 
AIM ONE: We hypothesize that TSP-1 is an anti-fibrotic target of interest and that 
shRNA mediated knockdown or pharmacological inhibition of TSP-1 with LSKL 
peptide will attenuate markers of fibrosis in TGFβ-1 activated primary human 
hepatic stellate cell activation in vitro. We also hypothesize that TSP-1 genetic 
deletion will decrease hepatic fibrosis in in vivo mouse model of NASH using Choline 
Deficient L-Amino Acid defined diet (CDAHFD). In our in vitro model using primary 
human hepatic stellate cell activation, we will quantitate expression of pro-fibrotic 
markers alpha smooth muscle actin (α-SMA) and Collagen I by immunofluorescence in 
TGFβ-1 activated primary human HSCs after shRNA knockdown of TSP-1 gene or after 
treatment with LSKL peptide, which inhibits TSP-1 mediated activation of latent TGFβ-
1. In our in vivo model of NASH with CDAHFD, we will measure hepatic fibrosis by 
histology, measure markers of inflammation and fibrosis by relative hepatic mRNA 
expression, measure serum lipid levels and serum liver function enzyme levels. We will 
also perform RNA-Seq on hepatic mRNA for transcriptomic analysis to characterize gene 
expression profiles impacted by CDAHFD and TSP-1 knockout in mice.  
AIM TWO: We hypothesize that key signaling pathways identified by tracking 
whole genome transcriptomic profile changes over 72 hours in TGF-β1 mediated 
primary human hepatic stellate cell activation and in anti-fibrotic inhibition with 
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bromodomain inhibitor JQ1 will lead to identification of anti-fibrotic target or 
pathway. Hepatic stellate cell activation is a key initiating step in fibrosis. We aim to 
identify important signaling pathways in hepatic stellate cell activation by RNA-Seq 
based whole genome transcriptomic profiling over 72 hours with data points at 0, 24, 48 
and 72 hours to identify significant pathways in both TGF-β1 activated HSCs and in 
HSCs treated with an anti-fibrotic tool compound, JQ-1. JQ1 is a bromodomain protein 
inhibitor and an anti-fibrotic tool compound. 
AIM THREE: We hypothesize that inhibition of signal transducer and activator of 
transcription 3 (STAT3) by Cpd188 will attenuate primary human hepatic stellate 
cell activation in vitro. We identify STAT3 as pathway of interest in Aim Two. STAT3 
has been shown to play a key role in myofibroblast activation in models of fibrosis in 
skin and lung. We will first validate that JQ1, a known anti-fibrotic tool compound, 
inhibits STAT3 phosphorylation in TGF-β1activated human primary HSC. We will  then 
validate STAT3 activation as an important signaling pathway in HSC activation by 
measuring markers of fibrosis (α-SMA and Collagen I) and viability in TGF-β1activated 
human primary HSCs treated with selective STAT3 inhibitor Cpd188. Cpd188 binds to 
STAT3 SH2 domain which inhibits STAT3  Tyr705phosphorylation and consequent 
JAK/STAT signaling. 
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CHAPTER TWO: MATERIALS AND METHODS 
Cell culture 
 Primary human hepatic stellate cells (HSCs) were purchased (ScienCell, Carlsbad, CA) 
and cultured with Stellate Cell Medium (ScienCell, Carlsbad, CA) in Collagen I coated 
flasks (Corning, Corning, NY) at 37◦ C in a humidified atmosphere containing 5% CO2. 
All experiments were performed with cells with passage number less than 8.  
Pharmacological Inhibitors  
JQ1 ((S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate) and Cpd188 (4-((3-
(Carboxymethylsulfanyl)-4-hydroxy-1-naphthyl)sulfamoyl)benzoic acid) were purchased 
from Sigma-Aldrich (Sigma-Aldrich, Saint Louis, Missouri). LSKL and SLLK peptides 
were purchased from Genscript (Genscript, Piscataway, NJ). 
Adenoviral shRNA transduction in primary human hepatic stellate cells 
HSCs were seeded into collagen coated 96-well plate (Corning, Corning, NY) at density 
of 10,000 cells/well in stellate cell medium (ScienCell, Carlsbad, CA), incubated for 24 
hours, and then transduced with adenoviral vector containing shRNA against THBS1 
(Vector Biolabs, Malvern, PA). Media was aspirated after 24 hours and then replaced 
with fresh media. All experiments were conducted 48 hours after transduction.  
Animals 
All procedures involving animals were reviewed and approved by the Pfizer Institutional 
Animal Care and Use Committee. C57BL/6J and TSP-1 knockout male mice of 5 weeks 
of age were purchased (The Jackson Laboratory, Bar Harbor, Maine) and were 
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acclimated for 1 week before initiating the diet. Animals were housed and acclimated 
under 12 hour light-dark cycles with free access to water. At day 0, C57/BL6 mice (The 
Jackson Laboratory, Bar Harbor, ME) or TSP-1 knockout mice (The Jackson Laboratory, 
Bar Harbor, ME,  Stock #006141) were provided with either control chow (Research 
Diets Inc., New Brunswick, NJ, Cat# A08051501) or CDAHFD chow (Choline deficient 
L-amino acid-defined high fat diet, Research Diets Inc., New Brunswick, NJ, Cat# 
A06071309) with 10-15 mice assigned per cohort (Table 1). Body weights were 
measured every 2 weeks. After 12 weeks all groups were euthanized by CO2 
asphyxiation. Sera were collected for liver enzymes and lipid level measurements.  
Whole livers were weighed and divided into three sections: left lateral lobe (LLL), right 
lateral lobe (RLL) and right medial lobe (RML). Sections were immersion fixed for slide 
preparation or snap-frozen in liquid nitrogen for RNA extraction. 
Tissue Collection, Slide Preparation and Staining 
At necropsy, one section each of LLL, RLL and RML from whole liver was taken and 
placed into a tissue cassette in 10% neutral buffered formalin for 48 hours and then 
switched to 70% ethanol until embedded in paraffin. Paraffin-embedded sections were 
cut and stained with Picrosirius red (PSR) or Hematoxylin and Eosin (H&E) for 
microscopic assessment by a board-certified veterinary pathologist. PSR stained slides 
were scanned using a Leica AT2 scanner (Leica Biosystems Inc., Wetzlar, Germany). 
Definiens Tissue Studio image analysis software (Definiens AG, Munich, Germany) was 
used to measure PSR staining, the areas of PSR staining was extracted from whole slide 
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images of the liver, and the results were exported as the area percentage of PSR staining  
in whole slide images. 
RNA extraction from mouse liver tissues for RNA-Seq and qRT-PCR 
RNA extraction was performed with TRIzol (Thermo Fisher Scientific, Waltham, MA) 
after homogenization with Omni TH tissue homogenizer (Omni International, Kennesaw, 
GA). The quality of the isolated RNA was assessed using Qubit Fluorimeter Qubit 2.0 
fluorimeter (Thermo Fisher Scientific, Waltham, MA) and Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA), respectively. 
HSC treatment and RNA extraction for RNA-Seq and qRT-PCR 
HSCs (passage number: 2) were seeded at 100,000 cells/well on Collagen I coated 12 
well plates (Corning, Corning, NY). After adhesion, cells were treated with 1uM JQ1 
(Cayman Chemical, Ann Arbor, MI) for 1 hour with 0.1% DMSO (Sigma Aldrich, St. 
Louis, MO) treatment as control treatment. After 1 hour, 300 ng/ml TGF-β1 was added to 
the media. At each time point, cells were washed by ice-cold PBS twice, then lysed in 
TRIzol (Thermo Fisher Scientific), and snap frozen in -80◦ C for storage prior to 
extraction. Each treatment and time points were in triplicates. RNA extraction was 
performed with QIAzol and RNeasy mini kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. The yield and quality of the isolated RNA was assessed using 
Qubit Fluorimeter Qubit 2.0 fluorimeter  and Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA), respectively. 
cDNA library construction and sequencing from mouse liver and HSCs 
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1 µg of RNA was used for cDNA library construction using a NEBNext Ultra Directional 
RNA library Prep Kit for Illumina (New England Biolab, Ipswich, MA, Cat# E7420S) 
according to the manufacturer's protocol. Size distribution was analyzed using an Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Qualified libraries 
were sequenced on an Illumina HiSeq 4000 Platform (Illumina, San Diego, CA, USA), 
using a paired-end 150 run (2x150 bases). 20M raw reads were generated from mouse 
liver libraries and 40M reads were generated from human HSC libraries. 
Pathway Enrichment Analysis for mouse liver RNA-Seq 
Dataset from Illumina HiSeq 4000 platform were processed and analyzed using 
QuickRNASeq as described previously [99]. RNA-Seq data were deposited in the Gene 
Expression Omnibus with the accession number GSE120977 and LIMMA R package 
was used for differentially expression analysis [100]. Differentially expressed genes 
(DEGs) were determined with false discovery rate threshold (FDR) <0.05 and genes with 
fold change greater than 1.5 (log2FC >0.58) were analyzed and visualized for enrichment 
and comparison analysis in Jomics (http://jomics.org).  
Pathway Enrichment Analysis for HSC RNA-Seq and published GEO DataSets 
Dataset from Illumina HiSeq 4000 platform were processed and analyzed using 
QuickRNASeq as described previously [99]. RNA-Seq data were deposited in the Gene 
Expression Omnibus with the accession number GSE117329 and tests for differentially 
expressed genes between any two conditions were performed by using likelihood ratio 
test module in edgeR [101]. Differentially expressed genes (DEGs) were determined with 
false discovery rate threshold of (FDR) <0.001 and genes with fold change greater than 
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1.5 (log2FC >0.58). Previously reported transcriptomic profiling of human NASH liver 
biopsies were acquired from GEO DataSets. DEGs from RNA-Seq analysis and GEO 
DataSets were analyzed and visualized in Jomics (http://jomics.org). 
Table 2-1. GSE # of human liver disease comparisons used in analysis. 
 
GSE# # of samples Platform 
GSE48452 73 samples of human liver 
grouped into C (control=14), H 
(healthy obese=27), S 
(steatosis=14) and N (NASH=18) 
Expression profiling 
by array 
GSE61260 134 samples of human liver Expression profiling 
by array 
GSE63067 18 samples of human liver with 
healthy=7, NASH=9 and 
steatosis=2 
Expression profiling 
by array 
 
Quantitative RT-PCR 
10 ng of RNA was used for reverse transcription and hybridization reactions with 
TaqMan probes and One step RNA-to-Ct kit on ViiA7 Real-Time PCR System (Thermo 
Fisher Scientific, Waltham, MA) according to manufacturer’s instructions. All HSC 
samples were run in three biological replicates with three technical replicates per 
experiment. All mouse liver samples were run in five biological replicates with two 
technical replicates per experiment. Relative  target gene expression was quantified using 
comparative CT ( 2-∆∆CT) method [102] with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, Gapdh) gene to normalize target gene expression. 
Protein Extraction and Western Blot 
Cells were washed twice in cold PBS-CMF (Thermo Fisher Scientific, Waltham, MA) 
then lysed in 1x cell lysis buffer (Cell Signaling Technology, Danvers, MA) 
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supplemented with cOmpleteTM Protease Inhibitor and PhosSTOPTM Phosphatase 
Inhibitor (Roche, Basel, Switzerland). Lysate was agitated for 30 minutes on ice and then 
centrifuged for 15 minutes at 4◦ C. Lysate supernatant was collected after centrifugation 
and total protein was measured using BCA Protein Assay Kit (Thermo Fisher Scientific, 
Waltham, MA). 30 µg of total protein was loaded onto NuPAGE 4-12% Bis-Tris Protein 
gel (Thermo Fisher Scientific, Waltham, MA) using 1x MES gel running buffer (Thermo 
Fisher Scientific, Waltham, MA). Post electrophoresis, the gel was blotted onto 
nitrocellulose membrane using iBlot 2 Gel transfer device (Thermo Fisher Scientific, 
Waltham, MA) and iBlot2 transfer stacks (Thermo Fisher Scientific, Waltham, MA). The 
membrane was blocked for an hour in Li-Cor Blocking Buffer –TBS (Li-Cor 
Biosciences, Lincoln, NE) and incubated overnight at 4°C in primary antibody; diluted 
1:1000 in blocking buffer (anti-phospho STAT3 Cat#9145;  anti-total STAT3 Cat#12640; 
anti-human THBS1 Cat# 37879; GAPDH Cat#5174, Cell Signaling Technology, 
Danvers, MA). After overnight incubation, the membrane was washed 3 times with 5 
minutes of agitation using TBS supplemented with 0.1% Tween20 (Sigma- Aldrich, Saint 
Louis, MO). The washed membranes were incubated at room temperature for an hour 
with secondary antibody (Li-COR IRDye 800 CW goat anti-rabbit IgG, Licor 
Biosciences, Lincoln, Nebraska, Cat# 925-32211) at 1:15,000 dilutions with blocking 
buffer. After incubation, the membranes were washed 3 times using TBS supplemented 
with 0.1% Tween20 (Sigma Aldrich, Saint Louis, MO), and final wash was with PBS-
CMF (Thermo Fisher Scientific). Stained and washed membrane was read on Li-Cor 
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Odyssey CLx imaging system (Li-Cor Biosciences, Lincoln, Nebraska). Densitometries 
of the blots were quantitated using Li-Cor software. 
 
Immunofluorescence 
 HSCs were seeded overnight in Viewplate Collagen I coated 96 well plates (Perkin 
Elmer, Waltham, MA) with Stellate Cell Media (ScienCell, Carlsbad, CA). The following 
day, HSCs were serum starved in stellate cell media supplemented with 0.3% FBS 
(ScienCell, Carlsbad, CA) overnight followed by TGF-β1 (R&D Systems, Minneapolis, 
MN) treatment for 48 hours. For peptide inhibition experiments, HSCs were treated with 
peptides 1.5 hours prior and then treated with TGF-β1. For pharmacologic inhibition 
experiments, HSCs were treated 1.5 hours prior to TGF-β1 treatment for 48 hours.  After 
48 hours, HSCs were fixed using ice-cold solution made of 50% acetone (Sigma- 
Aldrich, Saint Louis, MO) and 50% methanol (Sigma- Aldrich, Saint Louis, MO). The 
cells were blocked with PBS-CMF supplemented with 5% goat serum (Thermo Fisher 
Scientific, Waltham, MA) and 0.5% Triton-X (Sigma- Aldrich, Saint Louis, MO) for 30 
minutes. Following blocking the cells were stained with primary (α-SMA: Sigma 
Aldrich, Saint Louis, MO, Cat# A5228 ; Collagen I: Abcam, Cambridge, MA, Cat 
#ab6308) antibodies and secondary antibodies (goat anti-mouse IgG Alexa 568, Thermo 
Fisher Scientific, Waltham, MA, Cat# A11-004) diluted 1:1000 in PBS-CMF 
supplemented with 2.5% goat serum (Thermo Fisher Scientific, Waltham, MA) and 0.5% 
Triton-X  (Sigma- Aldrich, Saint Louis, MO)  for 1 hour each. Washes were performed 3 
times between each step using PBS-CMF (Thermo Fisher Scientific, Waltham, MA). 
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After staining, the cells were scanned on Operetta High Content Imaging System (Perkin 
Elmer, Waltham, MA). Mean fluorescence intensity per well was quantitated using 
Harmony Phenologic (Perkin Elmer, Waltham, MA) software and images were exported 
from Volocity (Perkin Elmer, Waltham, MA) software. All measurements were done in 
triplicates with 3 independent experiments. 
IL-6 ELISA 
HSCs were seeded into collagen coated 96-well plate (Corning, Corning, NY) at density 
of 10,000 cells/well in stellate cell medium (ScienCell, Carlsbad, CA), and incubated for 
24 hours. Cells were then treated with 1µM JQ1 or 0.01% DMSO for 1 hour, followed by 
treatment with 1µg/ml TGF-β1 (R&D Systems, Minneapolis, MN). After 24 hours, 
secreted IL-6 in the HSC culture supernatant was quantified using Quantikine IL-6 
ELISA kit (R&D systems, Minneapolis, MN) following manufacturer’s instructions.  All 
measurements were done in triplicates with 3 independent experiments. 
Cell Viability by tetrazolium salt (3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) assay 
HSCs were seeded into collagen coated 96-well plate (Corning, Corning, NY) at density 
of 10,000 cells/well in stellate cell medium (ScienCell, Carlsbad, CA), incubated for 24 
hours then treated with Cpd188 or 0.01% DMSO for 2 hrs. Following 2 hr. incubation, 
1µg/ml TGF-β1 was added. After 24 hours, Aqueous One Solution Cell Proliferation 
Assay (Thermo Fisher Scientific, Waltham, MA) was used to measure cell viability 
following manufacturer’s instructions. All measurements were done in triplicates with 3 
independent experiments. 
  
41 
Overexpression of STAT3 via Adenoviral transduction in primary human hepatic stellate 
cells 
HSCs were seeded into collagen coated 96-well plate (Corning, Corning, NY) at density 
of 10,000 cells/well in stellate cell medium (ScienCell, Carlsbad, CA), incubated for 24 
hours and then transduced with human STAT3 overexpression adenoviral vector with 
MOI of 300 (Vector Biolabs, Malvern, PA). Media was aspirated after 24 hours then 
replaced with fresh media. All experiments were conducted 48 hours after transduction.  
Apoptosis Assay 
HSCs were seeded on 96 well ViewPlate (Perkin Elmer, Waltham, MA) at density of 
10,000 cells/well in stellate cell growth medium, incubated for 24 hours, then treated with 
81 µM Cpd188 or 0.1% DMSO for 2 hours. Following incubation with inhibitors, 1 
µg/ml TGF-β1 was added and incubated for 24 hours. After 24 hours, cells were fixed 
and stained using Click-iT™ TUNEL Alexa Fluor™ 488 Imaging Assay, for microscopy 
& HCS (Thermo Fisher Scientific, Waltham, MA) and scanned on Operetta High Content 
Imaging System (Perkin Elmer, Waltham, MA). Mean fluorescence intensity per well 
was quantitated using Harmony Phenologic (Perkin Elmer, Waltham, MA) software, and 
images were exported from Volocity (Perkin Elmer, Waltham, MA)  software.  All 
measurements were done in triplicates with 3 independent experiments. 
Statistical analysis 
Data are presented as mean +/- standard error of the mean (SEM) with analysis 
performed using Student’s t test or analysis of variance (ANOVA) using GraphPad Prism 
version 7.04. (Sidak’s or Tukey’s multiple comparisons). Significance was set at p<0.05. 
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CHAPTER THREE: THROMBOSPONDIN-I AS A NOVEL THERAPEUTIC 
TARGET FOR NON-ALCOHOLIC STEATOHEPATITIS 
Section One: Abstract 
Non-alcoholic fatty liver disease (NAFLD) is a progressive liver disease 
characterized by dysregulated lipid metabolism and chronic inflammation ultimately 
resulting in fibrosis. Untreated, NAFLD may progress to non-alcoholic steatohepatitis 
(NASH), cirrhosis and death. However, currently there are no FDA approved therapies 
that treat NAFLD/NASH.  
 Thrombospondin-I (TSP-1) is a large glycoprotein in the extracellular matrix that 
regulates numerous cellular pathways including TGF-β1 activation, angiogenesis, 
inflammation and cellular adhesion. Increased expression of TSP-1 has been reported in 
various liver diseases; however, its role in NAFLD/NASH is not well understood. We 
first examined TSP-1 modulation in hepatic stellate cell activation, a critical initiating 
step in hepatic fibrosis. Knockdown or inhibition of TSP-1 attenuated HSC activation 
measured by α-SMA and Collagen I expression.  To investigate the impact of TSP-1 
modulation in context of NAFLD/NASH, we examined the effect of TSP-1 deficiency in 
choline deficient L-amino acid defined high fat diet (CDAHFD) model of NASH in mice 
by assessing total and liver weight, serum liver enzyme levels, serum lipid levels, liver 
steatosis, liver fibrosis and liver gene expression of wild type (WT) and TSP-1 knockout 
mice.  
CDAHFD fed mice, regardless of genotype, developed phenotypes of NASH, 
including significant increase in total and liver weight and liver enzymes, steatosis and 
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fibrosis. However, in comparison to WT, CDAHFD-fed TSP-1 deficient mice were 
protected against numerous NASH phenotypes. TSP-1 knockout mice exhibited a 
decrease in serum lipid levels, inflammation markers and hepatic fibrosis. RNA-Seq 
based transcriptomic profiles from the liver of CDAHFD fed mice determined that both 
WT and TSP-1 knockout mice exhibited similar gene expression signatures following 
CDAHFD, similar to biophysical and histological assessment comparison. Comparison of 
transcriptomic profiles based on genotype suggested that PPARα pathway and amino acid 
metabolism pathways are differentially upregulated in TSP-1 knockout mice. Activation 
of PPARα pathway was supported by observed decrease in serum lipid levels. Our 
findings provide important insights into the role of TSP-1 in the context of 
NAFLD/NASH, and TSP-1 may be a target of interest to develop anti-fibrotic 
therapeutics for NAFLD/NASH 
Section Two: Introduction 
 Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease with 
pathological presence of hepatic steatosis without established cause of hepatic fat 
accumulation such as alcohol and genetic disorders [103]. NAFLD is a growing health 
concern in the developed world; prevalence is estimated to be 30% of the population in 
the United States, with 70-90% of obese and diabetic affected individuals [55, 104, 105]. 
NAFLD also has numerous other co-morbidities such as insulin resistance, type II 
diabetes, and cardiovascular diseases that increase its clinical significance. NALFD-
related liver cirrhosis is projected to be the leading cause of liver transplantation in the 
United States by 2020 [104]. NAFLD is often asymptomatic; early detection remains a 
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challenge due to limitation in diagnostic approaches that are time consuming and 
invasive. Therefore, diagnosis of NAFLD is often made after significant advancement of 
diseases such as development of steatohepatitis, fibrosis, and cirrhosis and/or 
hepatocellular carcinoma. A better understanding of the mechanism behind progression 
of NAFLD is needed to develop successful therapies for NAFLD. 
In the development of fibrosis, myofibroblasts are key effector cells that generate 
the excess ECM in scar tissue. Activated hepatic stellate cells (HSCs) are the primary 
contributor of the pathogenic ECM production in hepatic fibrosis. Therefore, activation 
of HSC is a key step in fibrosis. Indeed, depletion of HSCs in murine models has shown 
remarkable attenuation of both hepatic fibrosis and reduced liver injury and 
inflammation, suggesting that activated HSCs play an additional role as amplifier of 
injury in addition to fibrogenesis [42]. Therefore attenuation of HSC activation may be a 
key pathway in developing novel anti-fibrotic therapeutics.  
 Thrombospondin I (TSP-1, THBS1) is a large secreted matricellular protein that 
interacts with a variety of ligands, including receptors, growth factors, proteases, 
cytokines and structural components of the extracellular matrix [73]. One of its well-
known functions is regulating pro-fibrotic cytokine TGF-β1 activity. TSP-1 knockout 
mice display similar but less extreme phenotypes of TGF-β1 deficiency, including 
multiple organ inflammation and epithelial hyperplasia [76]. 
In addition to TGF-β1 activation, TSP-1 is also important in numerous cellular 
functions such as angiogenesis, inflammation, cellular adhesion, migration, and growth. 
TSP-1 interacts with a variety of proteins, including its receptors CD36, CD47 and other 
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proteins of the extracellular matrix - including matrix metalloproteinases and integrins - 
to fulfill its many functions in the cell in a context-dependent nature. TSP1 also plays a 
critical role in ECM homeostasis by directly impacting collagen fibril formation by 
interacting with collagen, lysyl oxidase precursors and collagen cross linking sites [77]. 
TSP-1 expression is increased in various human fibrotic diseases and also highly 
expressed in adipose tissues in rodent models of obesity and in obese human patients [85, 
86]. Due to its role in fibrosis and metabolic dysregulation associated with obesity and 
diabetes, we hypothesized that TSP-1 may be an important modulator in NAFLD/NASH. 
One of the methods that closely replicate human NASH phenotype is choline deficient 
amino acid defined diet (CDAHFD). The diet is high in fat (60kcal%fat) with limited 
amount of methionine (0.1%) and lacks choline. Methionine and choline are necessary 
for hepatic secretion of triglycerides as VLDLs. In addition to a high fat diet, limiting or 
eliminating both result in impaired lipid export from the liver, which results in 
progressive development of hepatocellular steatosis, hepatocyte death, inflammation, 
oxidative stress and fibrosis, similar to typical disease manifestation and progression in 
human NASH [69].  
Here we examine the role of TSP-1 in NAFLD/NASH by comparing TSP-1 
deficient mice to WT mice in CDAHFD model of NASH. We first demonstrate that TSP-
1 inhibition/knockdown attenuate markers of fibrosis in primary human HSCs, a key 
myofibroblast precursor in hepatic fibrosis. We then determine that TSP-1 deficiency is 
protective against various NASH symptoms including hepatic fibrosis, mRNA markers of 
inflammation and serum lipid levels. Transcriptomic analysis of liver mRNA revealed 
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that TSP-1 deficiency results in upregulation of PPARα pathway and amino acid 
metabolism pathways. Our study suggests that TSP-1 may be an attractive target for 
NAFLD/NASH.  
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Section Three: Results and Discussion 
TSP-1 knockdown or inhibition attenuate markers of fibrosis in activated HSCs 
The activation of hepatic stellate cells (HSCs) to myofibroblasts is central to 
development of pathogenic fibrosis. To understand the role of TSP-1 in HSC activation, 
we utilized primary human hepatic stellate cells as our in vitro model system. HSC 
activation and differentiation into myofibroblasts can be measured by TGF-β1 dose 
dependent increase in α-SMA and Collagen I expression (Figure 3-1). We first confirmed 
that TSP-1 is induced by TGF-β1 treatment in our model system (Figure 3-2A) by 
Western Blot analysis. Quantification of densitometry determined that TSP-1 expression 
was significantly increased (242.6%, p =0.02) after primary human HSCs were treated 
for 48 hours with 1 µg/ml TGF-β1 (at a concentration >EC100 for α-SMA and Collagen 
I expression) compared to vehicle treated HSCs. To understand the impact of TSP-1 in 
HSC activation, we performed a knockdown experiment with THBS1 (gene for TSP-1) 
shRNA and measured markers of myofibroblast activation, α-SMA and Collagen I. 
Primary HSCs were transduced with THBS1 shRNA carrying adenoviral particles for 48 
hours followed by 1 µg/ml TGF-β1 treatment for another 48 hours. A control set of HSCs 
were transduced with scramble shRNA adenoviral particles. Following the transduction 
and TGF-β1 induced activation, Western Blot analysis confirmed successful knockdown 
(83%, p<0.0001) of TSP-1 protein expression (Figure 3-2B) compared to the control cells 
transduced with scramble shRNA. We then measured the impact of TSP-1 knockdown on 
activation of primary human HSCs by measuring Collagen I and α-SMA expression by 
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immunofluorescence at EC50 values of TGF-β1 mediated increase in Collagen I or α-
SMA by immunofluorescence (Figure 3-1). Next, HSCs were first transduced for 48 
hours with either shTHBS1 or scramble shRNA carrying adenovirus then treated with 50 
pg/ml (for Collagen I measurement) or 200 pg/ml (for α-SMA measurement) of TGF-β1, 
EC50 concentrations of TGF-β1 for inducing expression of Collagen I and α-SMA. Cells 
transduced with shTHBS1 adenovirus had attenuated α-SMA (75.5%, p<0.0001) and to a 
less extent Collagen I (92.6%, p=0.0287) expression in TGF-β1 activated primary human 
HSCs (Figure 3-2C) than cells transduced with scramble shRNA. These results from 
TSP-1 knockdown experiment suggest that TSP-1 is important in TGF-β1-mediated 
primary human HSC activation.  
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Figure 3-1. TGF-β1 concentration response with α-SMA and Collagen I expression 
in primary human HSCs.  
HSCs were treated for 48 hours with 9-0.001ng/ ml change to lowest to highest TGF-β1 
and then fixed and stained for α-SMA and Collagen I. Percent value is based on maximal 
response from addition of TGF-β1. EC50 α-SMA expression: 200 pg/ml TGF-β1; EC50 
Collagen I expression: 50 pg/ml TGF-β1. % expression values were calculated by 
defining zero as the smallest value in each data set and one hundred as the largest value 
in each data set. 
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Figure 3-2. Peptide-mediated inhibition or knockdown of TSP-1 attenuates markers 
of primary human HSC activation into myofibroblasts.  
A. Primary human HSCs activated with 1 µg/ml TGF-β1 for 48 hours show increased 
expression of TSP-1 by Western Blot analysis. Bar graph represent densitometry 
measurements, error bars show standard error of the mean (SEM). TSP-1/GAPDH 
expression was normalized to values from cells treated with vehicle (0.01% DMSO). B. 
Expression of TSP-1 is significantly reduced in TGF-β1 activated primary human HSCs 
transduced with adenoviral particles carrying shRNA against transcribed gene for TSP-1 
(shTHBS1) compared to HSCs transduced with control shRNA adenovirus. Cells were 
transduced at multiplicity of infection (MOI) of 300 for 48 hours prior to treatment with 
TGFβ then harvested after 48 hours.  Bar graph represent densitometry measurements, 
error bars show SEM. TSP-1/GAPDH was normalized to cells transduced with 
adenovirus carrying control shRNA. C. TSP-1 knockdown by shRNA transduction in 
primary human HSCs attenuate TGF-β1 mediated expression of markers of fibrosis, 
alpha smooth muscle actin (α-SMA) and Collagen I measured by immunofluorescence. 
HSCs were transduced with adenoviral shTHBS1(gene for TSP-1) for 48 hours then 
treated with TGFβ for 48 hours prior to fixation for immunofluorescence, n=3 per 
treatment per experiment. Error bars represent SEM; % expression is normalized to cells 
transduced with control shRNA. D. Treatment with inhibitory peptide against TGF-β1 
activating motif (LSKL) in TSP-1 results in attenuation of TGF-β1 mediated expression 
of markers of fibrosis, α-SMA and Collagen I. n=3 per treatment per experiment. Peptide 
with scrambled sequence (SLLK) does not significantly (n.s) impact expression of TGF-
β1-induced α-SMA or Collagen I. Error bars represent SEM; % expression is normalized 
to cells treated with vehicle (0.1% DMSO). All presented data are representative of at 
least 3 separate experiments. Statistical analysis was performed using GraphPad Prism v 
7.04 with either student’s t test or one way ANOVA Tukey’s multiple comparison tests. P 
value was considered significant at <0.05. 
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TSP-1 deficiency is protective in CDAHFD model of NASH 
TSP-1 is an important regulator of TGF-β1 activation in fibrosis. We examined 
whether the attenuation observed in the knockdown experiment may be attributed to TSP-
1 mediated TGF-β1 activation. TGF-β1 is secreted as a latent complex that requires 
activation in order to bind to its receptor, and with that binding triggers production of 
more TGF-β1, creating a positive feedback loop. To examine whether the inhibition of 
TSP-1 mediated TGF-β1 activation impacts HSC activation, HSCs were treated with 
3µM of inhibitor peptide (LSKL) that prevent the activation of secreted TGF-β1 followed 
by recombinant TGF-β1 (200 pg/ml for α-SMA and 50 pg/ml for Collagen I 
measurement). Scrambled peptide (SLLK) or vehicle (0.1% DMSO) treatments were also 
tested as controls. HSCs were fixed and stained for α-SMA and Collagen I after 48 hours 
and expression was quantified by immunofluorescence. Similar to our observation with 
TSP-1 knockdown in primary HSCs, there was a significant decrease in both α-SMA 
(86.7%, p=0.0126) and Collagen I (78.6%, p<0.0001) expression in LSKL treated cells 
compared to cells that were treated with vehicle 0.1% DMSO (Figure 3-2D). Treatment 
with scrambled peptide did not result in significant decrease in either marker of fibrosis. 
Therefore, attenuation of α-SMA and Collagen I observed in TSP-1 knockdown may be 
due to TSP-1’s role in activation of latent TGF-β1 as demonstrated by peptide mediated 
inhibition of TSP-1 mediated latent TGF-β1 activation.  
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Next, we explored whether modulation of TSP-1 impacts liver fibrosis in an in 
vivo model of a progressive fibrotic disease of the liver, non-alcoholic steatohepatitis 
(NASH). Briefly, 10-15 male C57/BL6J (wild type, WT) or TSP-1 knockout (TSP1 KO) 
mice were obtained and housed under 12h light dark cycles with free access to water and 
control or CDAHFD chow (Table 3-1). Body weight was measured every 2 weeks. After 
12 weeks, animals were euthanized for analysis. Serum samples were collected and livers 
were harvested, weighed, and divided into three different sections (right medial lobe, left 
lateral lobe, and right lateral lobe) that were immersion-fixed for slide preparation or snap 
frozen in liquid nitrogen. 
Table 3-1. Cohorts in the CDAHFD study with WT and TSP-1 knockout mice. 
Group ID N (# of mice) Diet Genotype 
Study 
duration 
NDWT 10 Control WT Weeks 1-12 
HFWT 15 CDAHFD WT Weeks 1-12 
NDKO 10 Control TSP1 KO Weeks 1-12 
HFKO 15 CDAHFD TSP1 KO Weeks 1-12 
After 12 weeks on control diet, TSP-1 knockout cohort compared to WT cohort 
did not differ in mean total body and liver weight (Figure 3-3B). Similarly, TSP-1 
knockout and WT mice fed CDAHFD did not differ significantly in total body and liver 
weight. However, there was a significant difference between cohorts fed CDAHFD vs. 
control diet in both genotypes, consistent with reports of weight gain and increase in liver 
weight that was previously reported [68]. Levels of ALT, AST and GLDH were 
significantly increased (****p<0.0001) in both WT and TSP-1 knockout groups fed 
CDAHFD (Figure 3-3C). However, serum aminotransferase levels were not significantly 
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different between TSP-1 knockout and WT in both diet cohorts, except GLDH levels 
were elevated (p=0.0003) in TSP-1 knockout mice fed CDAHFD compared to WT mice 
fed CDAHFD.  
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Figure 3-3. Body weight, liver weight and serum liver function enzyme level 
comparison of CDAHFD vs Control diet fed TSP1 KO and Wild type mice. 
 A. Both wild type (WT) and TSP-1 knockout mice (TSP1 KO) mice fed choline 
deficient L-amino acid defined high fat diet (CDAHFD) increased similarly in body 
weight with increase in time with heaviest weight at the time of sacrifice (week 12). Both 
WT and TSP-1 knockout mice fed control diet similarly did not show increase in body 
weight with increase in time. Both TSP-1 knockout and WT mice fed CDAHFD had 
significantly increased mean total body weight and liver weight compared to mice fed 
control diet. C. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
and glutamate dehydrogenase (GLDH) of CDAHFD vs. control diet fed mice were 
significantly increased in both WT and TSP-1 knockout groups. No significant difference 
was observed between TSP-1 knockout and WT groups fed control diet for ALT, AST 
and GLDH. In CDAHFD fed mice, TSP-1 knockout mice had significantly higher GLDH 
than WT. Each point represents a single animal. Statistical analysis is for each genotype 
group (TSP1 KO or WT) or for each diet group (CDAHFD or control); using one way 
ANOVA Tukey’s multiple comparison tests. Error bars represent standard error of the 
mean (SEM). P value was considered significant at <0.05. **** p<0.0001, ***p= 0.0003, 
*p=0.0325. 
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We then examined measurements of various lipid levels in the serum. Similar to 
serum liver-enzyme levels, there were significant differences between CDAHFD vs 
control diets (p<0.0001) in serum total cholesterol, low density lipoprotein (LDL) 
cholesterol, high density lipoprotein (HDL) cholesterol and triglyceride levels in both 
WT and TSP-1 knockout genotypes.  However, unlike total body weight, liver weights 
and serum liver-enzyme level comparisons, TSP-1 knockout compared to WT had 
significantly reduced total, LDL and HDL cholesterol in both control and CDAHFD diets 
(Figure 3-4A, B). However, no significant difference was observed between TSP-1 
knockout mice and wild type mice in both diet groups in triglyceride levels. 
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Figure 3-4. Lipid profile comparison of CDAHFD vs Control diet fed TSP-1 
knockout (TSP1 KO) and Wild type mice at 12 weeks.  
Comparison of serum levels of A. total cholesterol, B. Low density lipoprotein (LDL) 
cholesterol C. High density lipoprotein (HDL) cholesterol and D. Triglycerides 
measurements at week 12 of CDAHFD or control diet fed mice in both TSP1 KO and 
WT mice. Comparison between WT vs TSP1 knockout animals demonstrate significantly 
reduced serum cholesterol (total, LDL and HDL) levels in TSP-1 knockout vs WT in 
both control diet and CDAHFD fed cohorts. Each point represents a single animal. Error 
bars represent standard error of mean (SEM). Statistical analysis are for each genotype 
group (TSP1 KO or WT) or for each diet group (CDAHFD or control), using one way 
ANOVA Tukey’s multiple comparison tests ****p <0.0001 for all graphs, *p=0.0115 for 
cholesterol, ** p=0.0018, p=0.0241 for LDL cholesterol,   *** p= 0.0007 for 
triglycerides,   ns= no significance between compared groups  
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We then performed histologic analysis for hepatic steatosis and fibrosis by 
hematoxylin and eosin (H&E) and Picrosirius red (PSR) (Figure 3-5A, D). Importantly, 
quantification of percent PSR+ area revealed that TSP-1 knockout cohort had 
significantly less collagen and therefore reduced liver fibrosis (Figure 3-5B) than wild 
type. To determine whether the decreased fibrosis in TSP-1 knockout CDAHFD fed mice 
were due to decreased collagen mRNA expression, we performed qRT-PCR to measure 
relative mRNA expression of Col1a1 and Col3a1 with Gapdh as reference gene (Figure 
3-5C, Table 3-2). Interestingly, we did not see a significant difference in gene expression 
between CDAHFD fed TSP-1 knockout and WT at the 12 week time point (Figure 3-5C, 
Table 3-2). The difference between protein and mRNA collagen expression may be due 
to the length of the study; collagen mRNA may have been differentially regulated at an 
earlier time point whereas collagen detected by PSR may reflect the later stage events.  
To determine the effect of TSP-1 deficiency on liver inflammation, we also 
measured relative mRNA levels of the pro-inflammatory markers tumor necrosis factor 
(Tnf) and transforming growth factor beta 1 (Tgfb1). Relative expression of Tnf and 
Tgfb1 were subtly but significantly decreased in CDAFHD fed TSP1 knockout mice 
(Figure 3-5C, Table 3-2). There was no significant difference in the expression of col1a1, 
col3a1, Tnf and Tgfb1 between TSP1 knockout and WT mice fed control diet (Figure 3- 
5C, Table 3-2). 
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Figure 3-5. TSP-1 knockout mice are protected against CDAHFD induced liver 
fibrosis.  
A. Representative images of mouse liver sections stained with Picrosirius red (PSR).  B. 
TSP1 KO mice fed CDAHFD had significantly lower PSR+ area compared to WT mice 
fed CDAHFD (**** p<0.0001). The graphs were plotted as ratio of control group mean 
(using group mean of concurrent age matched control chow values for PSR). Statistical 
analysis was done using ordinary one-way ANOVA using multiple comparison (Sidak’s 
multiple comparison test) of selected pairs to compare control diet and CDAHFD groups 
from WT and TSP-1 knockout genotypes (total 2 selected pairs; control diet fed WT vs 
TSP-1 knockout mice; CDAHFD fed WT vs TSP-1 knockout mice) C. qRT-PCR 
analysis of collagen and inflammation markers from liver mRNA. Error bars represent 
SEM. Significance at p<0.05 NDWT: Control diet fed wild type mice. HFWT: CDAHFD 
fed wild type mice. NDKO: control diet fed TSP-1 knockout mice. HFKO: CDAHFD fed 
TSP-1 knockout mice. Relative fold change normalized to equivalent genotype fed 
control diet. Statistical analysis was done using ordinary one-way ANOVA using 
Tukey’s multiple comparison test with GraphPad Prism v. 7.04. D. Representative 
images of mouse liver sections stained with H&E. Bar represent 500 µm.  
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Table 3-2. Genes and TaqMan assay IDs used in qRT-PCR experiment. 
Gene Symbol Assay ID 
Tgfb1 Mm01178820 
Tnf Mm00443258 
Col1a1 Mm00801666 
Col3a1 Mm01254476 
Gapdh Mm99999915 
Liver mRNA transcriptomic analysis reveals upregulation of PPARα pathway and amino 
acid metabolism pathway in TSP-1 deficient mice   
To better understand the gene expression profiles in the various cohorts, we 
performed an RNA-Seq based transcriptomic analysis of poly (A) + mRNA extracted 
from the right lateral lobe of liver from 5 mice randomly selected from each group, with 
raw data deposited in gene expression omnibus (GEO) database with GEO accession 
number GSE120977. On average, 86% of raw sequenced reads were uniquely mapped to 
the mouse reference genome and 88% of the uniquely mapped reads were in genomic 
exon regions. The mapped reads were cut off at reads per kilobase per million reads 
(RPKM) >0.5. LIMMA R package was used in differentially expression analysis.  
Differentially expressed genes (DEGs) were determined by false discovery rate threshold 
(FDR) <0.05 and genes with fold change greater than 1.5 (log2FC>0.58). Overall, there 
were greater numbers of DEGs in diet comparisons than genotype comparisons 
suggesting that the difference in diet plays a greater, overwhelming role in mediating 
transcriptomic changes in the liver than difference in genotype (Table 3-2). 
 
 
 
  
63 
Table 3-3. Summary of DEG analysis based on diet and genotype comparisons. 
Comparison Cohort Upregulated Downregulated Total 
Genotype,  TSP-1 KO/WT CDAHFD 43 27 70 
Diet, CDAHFD/control TSP1 null 2894 1631 4525 
Diet, CDAHFD/control WT 2894 1960 4854 
Genotype, TSP-1 KO/WT control diet 288 251 539 
We first analyzed the impact of CDAHFD on relative changes in gene expression 
in TSP-1 knockout and WT mice. Venn analysis of DEGs TSP-1 knockout and WT 
cohorts revealed that the transcriptomic profiles of both comparisons were very similar, 
with 3794 DEGs overlapping between the comparisons with 731 DEGs unique to TSP-1 
knockout cohorts and 1060 unique WT cohorts (Figure 3-6A). Hierarchical clustering and 
heat map visualization of all DEGs based on fold change demonstrate that the 
directionality of gene expression changes in TSP-1 knockout and WT animals are very 
similar (Figure 3-6B). WikiPathways Analysis [106, 107] of the top ten up- and down-
regulated pathways further confirmed that CDAHFD fed TSP1 knockout and WT mice 
have many coinciding pathways with similar low p-values (Figure 3-6C). Some of these 
pathways that were upregulated include: extracellular matrix reorganization, metabolic 
dysregulation, injury/inflammation and proliferation such as focal adhesion, spinal cord 
injury, endochondral ossification, cholesterol biosynthesis, IL1 and megakaryocytes in 
obesity, MAPK signaling pathway and B cell receptor signaling pathways (Figure 3-6C).  
A difference was noted between TSP1 knockout and WT mice for pathways relevant to 
regulation of toll like receptor signaling pathway and retinoblastoma (RB) in cancer. A 
similar pattern was observed in the comparison of downregulated pathways with similar 
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adjusted p values in fatty acid beta oxidation, amino acid metabolism, PPARα pathway, 
one carbon metabolism and complement activation pathways. Overall the transcriptomic 
profiles of CDAHFD fed TSP1 and WT mice were similar with overlapping profiles 
indicative of pathological disruption, following the trend outlined earlier in total weight, 
liver weight, liver enzymes and histopathological analysis comparison. 
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Figure 3-6. Transcriptomic analysis to compare the impact of CDAHFD vs. control 
diet in gene expression profiles of TSP1 KO and WT mice.  
A. Venn diagram of differentially expressed genes (DEGs) from CDAHFD fed vs control 
diet fed TSP-1 knockout mice and WT mice. B. Heat map of fold change (log2FC) in 
DEGs (red: upregulated, green: downregulated) from genes in Figure 5A. C. Heat map 
with top 10 upregulated (in red) and downregulated (in blue) pathways by WikiPathways. 
DEGs were defined by FDR>0.05 and >1.5fold change comparing CDAHFD vs. control 
diet.  
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We then analyzed the impact of different genotypes on liver transcriptomic 
profiles in both control diet and CDAHFD groups. In these comparisons, gene expression 
from WT mice was used to define differentially expressed genes in TSP-1 knockout 
mice. Venn analysis of DEGs from both control diet and CDAHFD group revealed that 
there were only 36 DEGs that overlapped in control diet and CDAHFD (Figure 3-7A) in 
TSP-1 knockout mice. There are 34 unique DEGs in CDAHFD whereas 503 unique 
DEGs were identified in control diet (Figure 3-7A). A small number of DEGs (Table 3-3, 
70 total DEGs) with CDAHFD suggests that the liver transcriptomic profiles of both 
TSP-1 knockout and WT animals are heavily driven by CDAHFD and consequent 
pathogenesis, rather than by genotype. However, a greater number of DEGs defined 
(Table 3-3, 539 total DEG) from control diet fed TSP-1 knockout mice demonstrates that 
there are notable differences between transcriptomic profiles of TSP-1 knockout mice 
and WT mice. Furthermore, similarities in top ten up-and down-regulated pathways 
identified by Wiki Pathway Analysis between the two comparisons also confirm that the 
transcriptomic gene signatures driven by TSP-1 knockout genotype is maintained in both 
control and CDAHFD fed animals (Figure 3-7CB. The top ten upregulated pathways 
identified in TSP-1 knockout mice were pathways relevant to amino acid metabolism, 
PPARα pathway and fatty acid metabolism.The top ten downregulated pathways 
identified in TSP-1 knockout mice compared to WT were pathways relevant to 
retinoblastoma (RB) in cancer, cell cycle pathways and stress and injury mediated 
pathways.In addition, we also observed lung fibrosis pathway (which includes Tgfb) as 
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thirteenth downregulated pathway in CDAHFD fed TSP-1 KO vs WT comparison with –
log p value of -6.33 which further supports the decrease in fibrosis observed by PSR. 
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Figure 3-7. Transcriptomic analysis to compare the impact of TSP-1 KO vs. wild 
type genotype in control or CDAHFD diet fed mice.  
A. Venn diagram of differentially expressed genes (DEGs) from TSP1 KO vs WT mice 
fed CDAHFD or control diet. B. Heat map with top 10 upregulated (in red) and 
downregulated (in blue) pathways by WikiPathways. DEGs were defined by FDR<0.05 
and fold change >1.5 (log2FC>0.58) comparing TSP-1 knockout vs. WT mice.  
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To identify the pathways that may have contributed to observed decreased hepatic 
fibrosis in CDAHFD fed TSP-1 knockout mice, we then identified pathways that were 
modulated by CDAHFD that were also influenced in genotype comparison (Table 3-4). 
We identified PPARα pathway and amino acid metabolism pathways as pathways that 
were downregulated by CDAHFD in both genotype groups yet upregulated in TSP1 KO 
mice compared to WT mice in both diet conditions. We also determined the fold change 
values of specific genes in PPARα pathway (Figure 3-8) and amino acid metabolism 
pathway (Figure 3-9) as defined by WikiPathways to visualize the specific genes and 
their place in the pathways. In addition, we also identified fatty acid beta oxidation as a 
pathway similarly downregulated by CDAHFD in both genotype groups but the pathway 
was upregulated only in CDAHFD TSP-1 KO mice, suggesting that it is a pathway that is 
uniquely diet induced in TSP-1 knockout mice. In reverse, the Retinoblastoma (RB) 
cancer pathway was upregulated by CDAHFD but was repressed in wild type but not 
TSP-1 knockout mice suggesting that it was likely not a pathway that contributed to the 
anti-fibrotic effect of TSP-1 knockout.    
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Table 3-4. Summary of pathways of interest identified by WikiPathways 
Comparison Pathway Direction # of genes -log P 
WT: CDAHFD/control PPARα Pathway Down 12 23.7 
TSP-1 knockout: CDAHFD/control PPARα Pathway Down 8 14.3 
Control diet: TSP-1 knockout/WT PPARα Pathway Up 7 6.4 
CDAHFD: TSP-1 knockout/WT PPARα Pathway Up 5 7.5 
Comparison Pathway Direction # of genes -log P 
WT: CDAHFD/control Amino acid metabolism Down 17 16.7 
TSP-1 knockout: CDAHFD/control Amino acid metabolism Down  19 24.8 
Control diet: TSP-1 knockout/WT Amino acid metabolism Up 17 8.8 
CDAHFD: TSP-1 knockout/WT Amino acid metabolism Up 12 12.2 
Comparison Pathway Direction # of genes -log P 
WT: CDAHFD/control Fatty acid Beta Oxidation Down 14 25.6 
TSP-1 knockout: CDAHFD/control Fatty acid Beta Oxidation Down 8 12 
Control diet: TSP-1 knockout/WT Fatty acid Beta Oxidation n/a 3 0.8 
CDAHFD: TSP-1 knockout/WT Fatty acid Beta Oxidation Up 5 6.2 
Comparison Pathway Direction # of genes -log P 
WT: CDAHFD/control Retinoblastoma (RB) in Cancer Up 23 7.5 
TSP-1 knockout: CDAHFD/control Retinoblastoma (RB) in Cancer Up 27 11.4 
Control diet: TSP-1 knockout/WT Retinoblastoma (RB) in Cancer Down 19 11.5 
CDAHFD: TSP-1 knockout/WT Retinoblastoma (RB) in Cancer n/a 2 0.6 
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Figure 3-8. Visualization of log2FC values of genes identified in the four 
comparisons in PPARα metabolism pathway by WikiPathways.  
Rectangles with gene names are divided into four sections and colored according to 
direction and log2FC values of the four comparisons. Comparison 1 is WT: 
CDAHFD/control. Comparison 2 is TSP-1 knockout: CDAHFD/control. Comparison 3 is 
control diet: TSP-1 knockout/WT. Comparison 4 is CDAHFD: TSP-1 knockout/WT.  
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Figure 3-9. Visualization of log2FC values of genes identified in the four 
comparisons in amino acid pathway by WikiPathways. 
Rectangles with gene names are divided into four sections and colored according to 
direction and log2FC values of the four comparisons. Comparison 1 is WT: 
CDAHFD/control. Comparison 2 is TSP-1 knockout: CDAHFD/control. Comparison 3 is 
control diet: TSP-1 knockout/WT. Comparison 4 is CDAHFD: TSP-1 knockout/WT. FC: 
fold change 
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Here we describe the fibro-protective effect of TSP1 deficiency in an in vivo 
mouse model of NASH. We initially identified and validated TSP-1 as an anti-fibrotic 
target of interest by assessing the attenuation of in vitro primary human hepatic stellate 
cell activation by knockdown or pharmacological inhibition (Figure 3-2). To assess the 
impact of TSP1 deficiency in context of NASH, we chose CDAHFD model in mice. We 
observed CDAHFD fed TSP1 knockout mice to have numerous attenuated NASH 
symptoms, such as decreased serum lipid levels and markers of inflammation (Figure 3-
3). Importantly, we also observed that TSP-1 knockout mice had attenuated hepatic 
fibrosis by histological measurement (Figure 3-4). We found that the mRNA level of 
Collagen I and III, the most abundant type of collagen in fibrotic ECM deposits, not to 
differ between TSP-1 knockout and WT mice, which may be due to the kinetic difference 
in mRNA and protein changes in the 12 week study (Figure 3-4). Longitudinal study that 
collects samples for mRNA and protein expression analysis at different time points (e.g. 
0, 1, 4, 8, 12 weeks) during the study will be necessary to further characterize the 
discrepancy found in our study.  
Characterization and comparison of transcriptomic profiles of mice by genotype 
and diet revealed PPARα pathway (Figure 3-6) and mitochondrial dysfunction, 
specifically in amino acid metabolism and fatty acid beta oxidation (Figure 3-5), as 
pathways and mechanisms that were differentially modulated in TSP-1 knockout mice 
that may have provided protection against hepatic fibrosis in CDAHFD model of NASH 
in mice. Physiological observations such as decreased serum lipid levels and increased 
serum GLDH levels in TSP-1 knockout mice also supported modulation of these 
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pathways. Our results suggest TSP1 may be an attractive target in treatment of non-
alcoholic steatohepatitis. 
We observed a modest attenuation of recombinant TGF-β1 mediated primary 
human hepatic stellate cell activation in vitro by TSP-1 knockdown or by 
pharmacological inhibition of TSP-1. The modest attenuation may be due to the 
mechanism by which TSP-1 modulates TGF-β1 mediated HSC activation. TSP-1 
activates endogenously released latent TGF- β1 whereas recombinant TGF- β1 does not 
requires activation. To determine the impact of TSP-1 in TGF- β1 activated HSCs,  we 
utilized recombinant TGF-β1 at EC50 concentration to activate HSC and to initiate the 
release of endogenous TGF-β1. However, the existence of recombinant active TGF- β1 
may have partially masked the magnitude of TSP-1 knockdown/inhibition on the 
attenuation of activation markers.  
 TSP-1 has been identified as an important regulator in numerous fibrotic diseases 
induced by metabolic stress, such as type II diabetes induced diabetic nephropathy and 
cardiomyopathy. Our study, in reporting TSP1-1 deficiency as hepato-protective in a 
model of non-alcoholic steatohepatitis in mice, further implicates the role of TSP-1 as an 
important regulator in fibrosis and metabolic dysregulation. Our study observed that WT 
mice fed CDAHFD exhibit many symptoms of NASH including increase in body weight, 
liver enzyme levels, steatosis and fibrosis, consistent with previously reported results of 
CDAHFD in mice [68].  TSP-1 knockout mice also presented with similar NASH-like 
symptoms, however with statistically significant attenuation such as decreased serum 
lipid levels, markers of inflammation (p=0.02 for Tnf mRNA, p=0.01 for Tgfb1 mRNA) 
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and fibrosis (p<0.0001, percent area PSR). Serum liver enzyme AST and ALT were not 
different between TSP-1 knockout and WT mice; however, serum liver enzyme levels do 
not correlate to histological findings in clinical setting and are unhelpful in diagnosis of 
NAFLD and in determining the severity of the disease [108]. TSP-1 knockout mice fed 
CDAHFD also had increased GLDH levels, indicating perturbation in liver mitochondrial 
dysfunction with TSP-1 deficiency. TSP-1 knockout animals also had significantly lower 
serum total, LDL and HDL cholesterol level when compared to WT in both control diet 
and CDAHFD. However, we also observed that CDAHFD fed animals had lower serum 
lipids than those fed control diet, which seems contraindicative of a high fat diet. This is 
likely due to choline and methionine deficiency in the diet that impaired the release of 
VLDL from the liver to induce increased steatosis in the liver. Lastly, there was no 
significant difference observed between TSP-1 knockout and wild type mice in both diet 
groups in triglyceride levels suggesting that hepatic fatty acid uptake is not impacted by 
TSP-1 deficiency.   
Our study corroborates findings from a recent study examining the impact of 
TSP-1 in a model of obesity. TSP-1 knockout mice had significantly attenuated mRNA 
expression of inflammation markers TNF-α and TGF-β1 in adipose tissue from obese 
mice on non-choline deficient high fat diet [88] similar to our observation in the liver. 
Overexpression of TNF-α in adipose tissues correlate with insulin resistance in animal 
models, and insulin resistance correlate with onset of NAFLD/NASH. However, there 
were notable differences between the two studies.  Kong et al. reported attenuated weight 
gain and increased triglyceride levels in TSP-1 knockout mice whereas in our study there 
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was no difference between the genotypes in weight gain and triglyceride levels [88]. This 
difference may be due to the differences in the diet utilized in the study. High fat chow in 
the study on TSP-1 impact on adiposity consisted of 60% fat and 20% carbohydrates that 
did not induce hepatic fibrosis whereas chow used in our study consisted of 60% fat with 
choline deficiency and limited methionine which induces robust induction of hepatic 
fibrosis.  
In our transcriptomic analysis, we observed upregulation of peroxisome 
proliferator activated receptor alpha (PPARα) pathway in CDAHFD fed TSP-1 knockout 
mice. PPARα is a central negative regulator of lipid metabolism and inflammation. It is a 
ligand activated nuclear receptor/transcription factor in the same NR1C nuclear receptor 
family as PPARγ and PPARβ/δ. PPARα activation by ligand binding results in inhibition 
of inflammation whereas deficiency results in enhanced inflammation [109, 110]. In the 
liver, where it is highly expressed, PPARα is also a critical regulator of lipid metabolism. 
Many PPARα target genes are involved in fatty acid metabolism in muscle, heart and 
liver. Previously, it was reported that PPARα deficiency in mice results in elevated 
production of TSP-1 by inflammatory leukocytes in the plasma [111]. In our 
transcriptomic study, we observed upregulation of genes in PPARα pathway in TSP-1 
deficient mice. Fatty acid oxidation pathway, a pathway that is also positively regulated 
by PPARα activation [112], was also observed to be upregulated in TSP-1 knockout 
animals, further implying modulation of PPARα pathway with TSP-1 deficiency. In 
addition, TSP-1 knockout mice had lower serum lipid levels (LDL, HDL and total 
cholesterol) which are also indicative of PPARα activation. Lastly, obese insulin-resistant 
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patients treated with pioglitazone, a PPARγ and PPARα agonist approved to treat type II 
diabetes, also exhibit decreased TSP-1 expression [86]. 
 Our transcriptomic and physiological data, in conjunction with the study on 
PPARα deficient mice and obese insulin resistant patients, suggests an inverse 
relationship between TSP-1 and PPARα pathway, specifically in lipid metabolism where 
negative modulation of TSP-1 activates PPARα pathway and vice versa. Previously, 
PPARα has not yet been directly linked with TSP-1. However, CD36, a receptor of TSP-
1, is involved in fatty acid uptake that is under transcriptional control of PPARγ. PPARγ 
agonists, which are also often PPARα agonists, increase CD36 expression [113]. 
However, we did not observe a difference in PPARγ pathway between TSP-1 knockout 
and WT mice in our transcriptomic analysis. Whether TSP-1/PPARα modulation is 
related to TSP-1/CD36 interaction needs further investigation. Mechanistic investigation 
into TSP-1 induced PPARα modulation in the liver will lead to greater insight into the 
relationship between dysregulated lipid metabolism and consequent hepatic fibrosis.  
We observed that TSP-1 KO mice exhibited dramatically decreased hepatic 
fibrosis in vivo; however, we observed modest attenuation of fibrotic markers in TSP-1 
knockdown/inhibition in TGF-β1 mediated HSC activation in vitro. The difference 
between in vivo and in vitro results may be due to additional systemic impact of TSP-1 
deficiency in fibrotic pathways, in addition to its role in TGF-β1 activation, such as 
activation of PPARα pathway. The in vitro model system utilizing HSCs did not capture 
possible cross talks that may exist between different cell types with HSCs, such as 
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hepatocytes and Kupffer cells. Furthremore,  surrounding adipose tissues and the gut, can 
influence and modulate metabolic and inflammatory signals to the liver to influence 
hepatic fibrosis. Additional experiments to explore the impact of PPARα agonism in 
TGF-β1 mediated HSC activation in vitro and further investigation into cell type- and/or 
liver- specific TSP-1 KO in vivo may elucidate insights into the discrepancy observed 
between in vitro and in vivo results.  
Our transcriptomic analysis of CDAHFD fed TSP-1 knockout mice also indicated 
modulation of amino acid metabolism pathway. Liver is the site of synthesis and 
catabolism of protein and amino acid where the mitochondria play a key role via the 
tricarboxylic acid (TCA) cycle, ATP synthesis and mitochondrial respiration [114]. 
Increased amino acid concentrations have been associated with increased risk of 
metabolic diseases such as type 2 diabetes and NAFLD [115].  \Plasma free amino acid 
profiles have also been correlated with progression of fatty liver diseases with NASH 
patients exhibiting highest values [64]. Significant decrease in genes associated with 
branched chain amino acid catabolism and fatty acid beta oxidation has been observed in 
NAFLD patients [116] which correlates with our data comparing CDAHFD fed mice 
with control diet fed mice that also showed downregulation of fatty acid beta oxidation 
and amino acid metabolism. Therefore, dysregulated amino acid metabolism is associated 
with development of NAFLD/NASH. However, the exact mechanism behind how 
dysregulated amino acid metabolism contributes to NAFLD is not well defined. 
  
79 
Interestingly, Soto-Pantoja et al. also recently reported differentially regulated 
elements of mitochondrial dysfunction in TSP-1 knockout mice. Amino acid and lipid 
metabolism as well as and ketone body formation were identified by global metabolic 
profiling study that examined the impact of TSP-1 deficiency combined with high fat diet 
[117]. Specifically, in TSP-1 deficient liver, ketogenic amino acid and lipid metabolism 
changes associated with dysregulated TCA cycle were observed, suggesting 
mitochondrial dysfunction in TSP-1 knockout mice [117]. Similarly, we also observed an 
increase in serum glutamate dehydrogenase (GLDH) in TSP-1 knockout animals fed 
CDAHFD. GLDH is an enzyme important in amino acid oxidation and urea production 
pathway. [118]. McGill et al. recently proposed GLDH as a biomarker of liver 
mitochondrial dysfunction as increased GLDH serum concentration was observed in mice 
with hepatic injuries [119, 120]. Our study indicated an increase in GLDH in TSP-1 
knockout nice fed CDAHFD, also suggesting a possible increased mitochondrial 
dysfunction with TSP-1 deficiency. However, our transcriptomic data suggests 
upregulation of amino acid metabolism and fatty acid beta oxidation in TSP-1 deficient 
mice which suggests improved mitochondrial function. A key difference to note between 
our study and Soto-Pantoja et al. is that their study examined impact of high fat diet on 
TSP-1 deficiency in Apc min/+ mice, whereas our study examined the impact of high fat, 
choline deficient model of hepatic fibrosis with TSP-1 deficiency in C57BL/6J 
background.  The differences in genotypes and disease model may lead to different 
activation of various pathways modulated by TSP-1. Because mitochondrial dysfunction 
may be manifested in numerous ways, it is also possible that TSP-1 deficiency may 
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improve one facet such as amino acid metabolism while worsening another such as 
ketogenesis. Based on our data and the data from Soto-Pantoja et al., TSP-1 modulation 
clearly impacts mitochondrial function in the context of metabolic stress. However, 
further investigations are necessary to elucidate mechanisms and physiological meaning 
underlying the relationship between TSP-1, amino acid metabolism, and mitochondrial 
dysfunction in NAFLD. 
Section Four: Concluding Remarks 
Our study suggests that TSP-1 plays an important role in NAFLD/NASH by 
modulation of PPARα pathway. PPARα has recently been identified as a target of interest 
and a new potential therapeutic area for NAFLD/NASH. Activation of PPARα in 
combination with PPARβ/δ improves steatosis, inflammation and fibrosis in a preclinical 
model of non-alcoholic fatty liver disease [121]. Fibrates are a class of PPAR agonists 
that are approved for treating various dyslipidemias such as hypercholesterolemia by 
reducing very low density lipoproteins (VLDL) production in the liver. Fenofibrate 
treatment of patients with NALFD resulted in reduction of elevated ALT, AST and γGT 
plasma levels and hepatocellular ballooning in some patients; however, steatosis, 
inflammation and fibrosis were not significantly changed [122]. Treatment of NASH 
patients with another fibrate, gemfibrozil, also lowered ALT, AST and γGT [123]; 
however, in contrast, clofibrate, another PPAR agonist, did not improve ALT, AST, γGT 
or histological assessment of steatosis inflammation and fibrosis [124]. Another PPARα 
and PPARγ agonist compound, pioglitazone, was found to improve NAFLD in diabetic 
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and non-diabetic patients [125, 126]. The differences observed in outcomes with various 
PPAR agonists may be due to differences in their selectivity for PPAR receptor subtypes. 
Further investigations into the mechanism of PPARα activation, possibly via TSP-1 
modulation, in NASH-induced liver fibrosis may be beneficial in the development of 
novel therapies for NASH. 
We also observed modulation of mitochondrial function in TSP-1 knockout mice. 
Mitochondrial dysfunction as a target has also been recently explored as a treatment 
strategy for NASH. Mitochondrial oxidative metabolism and hepatic inflammation were 
observed to be closely linked [127]. Furthermore, targeting mitochondrial function in 
animal studies has shown reduction in hepatic steatosis, necrosis, inflammation and 
fibrotic progression in NASH [127, 128]. However, whether these studies are directly 
translatable to human disease has not yet been explored.  
In summary, our study demonstrates that TSP-1 plays a role in NAFLD/NASH 
and modulates PPARα pathway and amino acid metabolism in vivo, as well as hepatic 
stellate cell activation in vitro. TSP-1 deficiency attenuated hepatic fibrosis and other 
NAFLD symptoms such as serum lipid levels and inflammation markers. Furthermore, 
TSP-1 deficiency mediated modulation of PPARα pathway in CDAHFD induced hepatic 
fibrosis were observed in both physiological and transcriptomic data. Although amino 
acid metabolism was identified in transcriptomic analysis, the exact role of its modulation 
and impact on NAFLD/fibrosis must be investigated further. In combination with 
corroborative findings by other studies examining the role of TSP-1 and metabolic 
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dysfunction mediated fibrosis [82, 83, 88, 129, 130], our study suggests that TSP-1 may 
be an attractive target for NASH-induced hepatic fibrosis.   
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CHAPTER FOUR: TRANSCRIPTOMIC ANALYSIS OF IN VITRO ACTIVATED 
HUMAN PRIMARY HEPATIC STELLATE CELLS 
Section One: Abstract 
 Hepatic fibrosis is characterized by the accumulation of scar tissue that damages 
and disrupts organ architecture and function. The scar tissue is the end result of 
prolonged inflammation and injury from various causes such as viral infection, alcohol 
and drug abuse, toxins and metabolic stress. Ultimately, the progression of hepatic 
fibrosis results in cirrhosis, organ failure and death. Activation of hepatic stellate cells 
(HSCs) leading to differentiation into myofibroblasts is a key event in hepatic fibrosis; 
activated HSC derived myofibroblasts are a primary producer of extracellular matrix 
(ECM) deposits that make up the scar tissue in the liver. To better understand the 
molecular mechanisms and critical pathways involved in HSC activation and transition 
into myofibroblasts, we modeled initiating events in hepatic fibrosis by treating HSCs 
with a pro-fibrotic cytokine, transforming growth factor-beta (TGF-β1), and performed a 
longitudinal gene expression profile of primary human HSCs to elucidate key pathways 
activated during initiating signaling events. To identify activated pathways that are 
downregulated upon suppression of pro-fibrotic response and progression, we performed 
a parallel co-treatment with TGF-β1 and a potent anti-fibrotic epigenetic modulator, JQ1. 
Our comparative analysis of these two parallel experiments identified the Signal 
Transducer and Activator of Transcription 3 (STAT3) signaling pathway as an activated 
pathway of interest. Pharmacological inhibition of STAT3 signaling using a STAT3 
specific inhibitor, Cpd188, impacted cell viability by promoting apoptosis in activated 
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HSCs. These findings provide important insight into discovery of future anti-fibrotic 
therapeutics and demonstrate the importance of activated STAT3 in promoting a pro-
fibrotic phenotype. 
Section Two: Introduction 
In this study we aimed to use transcriptomic analysis to identify possible anti-
fibrotic targets, specifically, by analyzing gene expression changes during hepatic stellate 
cell activation and under anti-fibrotic repression. Transcriptomic analysis can provide 
global information on the dynamic changes in gene expression at specific time points 
from diverse sample types including cell lines, pre-clinical models and human clinical 
samples. Upon treatment with TGF-β1, hepatic stellate cells undergo a tightly 
programmed response with hallmark phenotypic changes such as expression of 
cytoskeletal protein α-SMA and increased deposition of ECM matter. Previous 
transcriptomic analysis performed on primary mouse [131] or rat HSCs [132]  or 
immortalized human hepatic stellate cell lines such as LX-2 [133] has revealed innate 
immune response and lipid metabolism as important pathways in hepatic stellate cell 
activation. Markers of liver fibrosis have also been explored using transcriptional analysis 
of  human hepatic stellate cells [134]. Recent innovations in transcriptomic technologies 
such as RNA-Seq has greatly advanced the knowledge on complexities of eukaryotic 
transcriptomes [135]. Therefore, we hypothesized that comprehensive transcriptomic 
analysis of TGF-β1 mediated HSC activation by RNA-Seq will provide valuable insight 
into HSC activation to afford us the opportunity to identify pathways or targets that can 
ameliorate hepatic fibrosis progression. 
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In addition to developing molecular insights into genes modulating HSC 
activation and fibrogenic progression, understanding the driving forces that halt and/or 
reverse fibrotic progression would provide valuable insight into discovery of novel 
targets to attenuate pathogenic fibrosis in the liver. Previously, whole genome wide 
chromatin immunoprecipitation sequencing (Chip-Seq) studies of mouse primary HSCs  
determined that the epigenetic modulator bromodomain-containing protein 4 (BRD4) 
associates with acetyl-histone H3K27 marked enhancers for a variety of well-established 
pro-fibrotic genes and pathways in HSCs including focal adhesion, smooth muscle 
contraction, as well as NFκB and JNK/MAPK pathway activation  [136] . Administration 
of small molecule BRD4 inhibitor, JQ1, also exerted potent anti-fibrotic effect in a mouse 
model of hepatic fibrosis [136]. JQ1 inhibits BRD4 by occluding bromodomain acetyl-
lysine binding pockets to disrupt assembly of chromatin complexes. JQ1 has been 
validated as an effective anti-fibrotic tool reagent in various model systems of fibrosis 
and is a powerful tool compound to further elucidate other specific targets and pathways 
that can be modulated to attenuate fibrosis.  
Recently STAT3 has been identified as a target of interest in hepatic fibrosis. In 
the liver, STAT3 activation in HSCs contributes to progression of hepatic fibrosis by 
promoting HSC survival, proliferation and activation [96, 137].  STAT3 is a highly 
conserved transcription factor that modulates both innate and adaptive immunity by IL-6 
family of cytokines and other cytokines such as IL-10, IL-11, IL-17, IL-22 and IL-23 
[138]. Upon binding of these cytokines to their cognate receptors, STAT3 is 
phosphorylated by JAK family kinases which initiate dimerization, translocation to 
  
86 
nucleus and initiation of target gene transcription. STAT3 modulated genes are involved 
in fundamental cellular processes such as inflammation, cell growth, proliferation, 
differentiation, migration and apoptosis and are context dependent on cell type in which 
roles they serve [93].  
  Here, we performed a comparative longitudinal transcriptomic analysis of a) 
primary human HSCs undergoing activation and transition into myofibroblasts via 
treatment with TGF-β1 and b) HSCs co-treated with TGF-β1 and JQ1 to characterize the 
dynamic gene expression changes under pro- vs. anti-fibrotic progression (Figure 4-1). 
By comparative analysis of these parallel gene expression profile changes over time, we 
identified STAT3 signaling as a key event in TGF-β1 mediated HSC activation and 
differentiation into myofibroblast. We further validated the critical role of STAT3 
signaling in fibrosis by demonstrating that inhibition of STAT3 impacts cell viability by 
increasing apoptosis that signals for resolution of fibrosis in primary human HSCs. Our 
data suggest that STAT3 signaling may be a promising pathway of interest in developing 
novel anti-fibrotic therapeutics. 
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Figure 4-1. Schematic of RNA-Seq experiment set up 
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Section Three: Results and Discussion 
Primary human hepatic stellate cells treated with TGF-β1 model pro-fibrotic progression 
in human liver.  
To better understand the dynamics of gene expression changes in hepatic stellate 
cell activation over time, we performed a longitudinal gene expression profiling of 
primary human hepatic stellate cells treated with and without 300 ng/ml TGF-β1 at 0, 24, 
48 and 72 hours using RNA-Seq. Briefly, poly (A) + mRNA were sequenced using 
Illumina Hiseq 4000 platform with 40 million clean reads generated from each library 
(biological replicate n=3 per treatment). On average, 96.7% of raw sequenced reads were 
uniquely mapped to the human reference genome (GRCh38.p12) and 90 % of the 
uniquely mapped reads were in genomic exon regions. The mapped reads were cut off at 
reads per kilobase per million reads (RPKM) >0.5. Differentially expressed genes were 
determined by comparison to expression without any TGF-β1 treatment at equivalent 
time points with false rate discovery >0.001 and log fold change >0.58. Detailed 
information regarding processing of the raw data and DGE identification were deposited 
in the following URL (https://interactivereport.github.io/HSCTGFB). Raw RNA-Seq data 
were also deposited in the Gene Expression Omnibus (GEO) database with GEO 
accession number GSE117329. We first sought to validate our model system of primary 
hepatic stellate cells by comparing upregulated gene expression changes at various time 
points after TGF-β1 treatment to publically available gene expression profiles of biopsies 
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from patients with non-alcoholic steatohepatitis (NASH) from 3 different studies listed in 
Table 4-1. [139-141] 
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Figure 4-2. Primary human hepatic stellate cells treated with TGF-β1 model pro-
fibrotic progression in human liver.  
A) Top 10 gene ontology (GO) biological process terms identify immune system and 
related pathways as enriched in comparison of publically available gene expression 
dataset from non-alcoholic steatohepatitis (NASH) biopsies and 300 ng/ml TGF-β1 
treated HSC. B) Genes associated with inflammation and myofibroblast differentiations 
are upregulated in TGF-β1 treated hepatic stellate cells. C) Venn diagram analysis of 
upregulated genes with TGF-β1 treatment show sets of early, mid and late-arising genes. 
False rate discovery was set at <0.001 and log fold change at >0.58 for differentially 
expressed genes compared to gene expression from non-treated cells. D) Ingenuity 
Pathway Analysis (IPA) of 107 genes that are identified in the intersection of upregulated 
genes at all 3 time points reveal pathways in inflammatory diseases and hepatic stellate 
cell activation as top canonical pathways.  
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Overlay of gene ontology (GO) pathway analysis [142] of the 6 datasets (3 NASH 
biopsies, HSCs at 24, 48 and 72 hours post TGF-β1  treatment) revealed enrichment of 
genes involved in  immune system process and other immune system related pathways 
including defense response and  regulation of immune process (Figure  4-2A). 
Similarities observed across all the datasets also suggested that human primary HSCs 
undergo globally comparable gene expression profile changes as fibrotic liver samples 
and highlight the critical role of the immune response and inflammation in fibrosis. 
Consistent with the GO analysis, TaqMan analysis (Table 4-2) revealed that genes 
associated with inflammation and pro-fibrotic progression such as pro-inflammatory 
cytokines IL6, IL32, IL1A and myofibroblast markers COL1A1 and ACTA2 were 
upregulated in TGF-β1 treated HSCs (Figure 4-2B). We did not examine IL1B in our 
TaqMan analysis because our RPKM values for IL1B in RNA-Seq data did not reflect 
increase in IL1B gene expression in TGF-β1 activated HSCs.  
 
Table 4-1. Genes and TaqMan Assay IDs used in qRT-PCR to analyze gene 
expression in HSCs. 
Gene Symbol Assay ID 
GAPDH Hs02786624_g1 
ACTA2 Hs00426835_g1 
COL1A1 Hs00164004_m1 
IL1A Hs00174092_m1 
IL6 Hs00174131_m1 
IL32 Hs00992441_m1 
LIF Hs01055668_m1 
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We then performed Venn diagram analysis of all genes upregulated (false rate 
discovery <0.001 and with at least 1.5 fold gene expression change, log fold change 
>0.58 from untreated HSCs at equivalent time point) in primary human HSCs after TGF-
β1 treatment. The number of upregulated genes increased with time as primary HSCs 
underwent trans-differentiation into pro-fibrotic myofibroblasts (Figure 4-2C) with 300 
ng/ml TGF-β1 treatment. There were also increases in genes uniquely upregulated at each 
time point illustrating the distinctive dynamics of gene expression changes during 
initiation and progression of HSCs into extracellular matrix producing myofibroblasts. In 
contrast to genes that underwent dynamic changes in gene expression over time, there 
were 107 genes that were consistently upregulated at all time points which suggested that 
they may play a critical role in both initiation and progression into myofibroblasts.  
Analysis of these genes using Ingenuity Pathway Analysis software revealed top 
canonical pathways related to inflammation such as osteoarthritis (p = 1.98E-5, 8/199 
genes associated with pathway), IL-17 signaling (p=9E-5 4/41 genes associated with role 
of IL17F in allergic inflammatory airway diseases pathway, 1.49E-5 4/85 genes 
associated with IL-17 signaling  pathway) and hematopoiesis (p=1.7E-5, 3/41 genes 
associated with hematopoiesis from pluripotent stem cells pathway) and as expected, 
hepatic stellate cell activation (p=7.44E-5, 7/177 genes associated with pathway) (Figure 
1D).  
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Comparison of upregulated genes undergoing pro-fibrotic progression to downregulated 
genes under anti-fibrotic suppression reveals inhibition of STAT3 signaling pathway as 
one of the key initiation events in fibrotic suppression. 
Administration of the small molecule BRD4 inhibitor, JQ1, shows a potent anti-
fibrotic effect in HSCs and mouse model of hepatic fibrosis [136]. JQ1 modulates 
epigenetic regulation by BRD4, which impacts a broad range of genes and pathways. We 
aimed to dissect specific genes modulated by JQ1 treatment that exerted anti-fibrotic 
effects in HSCs by performing a longitudinal experiment. We hypothesized that genes 
that are normally upregulated in activation that are repressed early and remain repressed 
will be the genes driving the anti-fibrotic effect of JQ1. We first validated JQ1’s efficacy 
as an anti-fibrotic compound in our model system of primary human hepatic stellate cells 
in culture by immunofluorescence. When primary HSCs were treated for 48 hr. with 1uM 
JQ1 and TGF-β1 (50 pg/ml for collagen measurement or 200 pg/ml for α-SMA 
measurement), we observed significantly attenuated α-SMA expression and Collagen I 
deposition (Figure 4-3A) by immunofluorescence compared to treatment with TGF-β1 
without JQ1. We then compared longitudinal gene expression profiling of primary human 
hepatic stellate cells treated with 300 ng/ml (>EC100 for α-SMA and Collagen I in 
immunofluorescence) TGF-β1 or 300 ng/ml TGF-β1 and 1µM JQ1 treatment at 0, 24, 48 
and 72 hours using RNA-Seq (gene expression of untreated cells at equivalent time was 
set as reference point).  We analyzed the genes upregulated with TGF-β1 and 
downregulated with JQ1 by hierarchical clustering and visualized the result as a heat map 
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(Figure 4-3B).  The longitudinal analysis showed that treatment of JQ1 resulted in 
gradual suppression of the majority of TGF-β1 induced genes with time.  
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Figure 4-3. Comparisons of induced genes in primary human hepatic stellate cells 
undergoing pro-fibrotic progression that are inhibited by JQ1 reveal IL-6 family of 
cytokine signaling and STAT3 phosphorylation as important in fibrotic progression.  
A) 1uM JQ1 treatment significantly attenuates markers of fibrosis α-SMA and Collagen I 
deposition measured by immunofluorescence in primary human HSCs treated for 48 hr. 
with 200pg/ml and 50pg/ml TGF-β1 respectively. B) Hierarchical clustering of genes 
induced with TGF-β1 and repressed with JQ1. Most genes that are upregulated with 300 
ng/ml TGF-β1  are repressed by 24-72 hours when 1uM JQ1 is added in addition to TGF-
β1  to HSCs. C) Venn diagram analysis of genes upregulated with TGF-β1  at all time 
points and downregulated with 24 hours of JQ1 and TGF-β1  treatment reveal 26 
common genes amongst all 4 datasets. These genes may play a critical role in fibrotic 
progression and repressing them may be a key step in mounting an anti-fibrotic response. 
D) qRT-PCR confirmed that markers of fibrosis (ACTA2, COL1A1) and inflammatory 
genes are upregulated with TGF-β1 but downregulated with JQ1 treatment. mRNA was 
collected after 24 hours of treatment and gene expression is relative to GAPDH. IL1A, 
IL6, IL32 and LIF are upregulated at all time points with 300 ng/ml TGF-β1 and 
downregulated within 24 hours of 1 µM JQ1 and 300 ng/ml TGF-β1 treatment. Error bars 
represent upper and lower limits of the mean; data is representative of 3 separate 
experiments. E) Expression of IL-6 increases with increasing concentration (0.01-10 
ng/ml) of TGF-β1 and inhibited by addition of 1 µM JQ1. Error bars represent standard 
error of mean (SEM). Data are representative of 3 separate experiments. F)  1 µM JQ1 
treatment inhibits TGF-β1 mediated STAT3 phosphorylation in human primary HSCs by 
Western Blot analysis. G) Bar graph representing densitometry from Western blot in 
Figure 2G, n=3; error bars represent standard error of the mean (SEM).   Presented data 
are representative of 3 separate experiments. Phosphorylated STAT3 level were 
determined by first normalizing phospho STAT3 and total STAT3 densitometry to levels 
of GAPDH and then by ratio of normalized phospho STAT3 to total STAT3. **** 
p<0.0001 by ANOVA, significance at p<0.05 
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To understand which genes are important in the early initiating phase of 
suppression of pro-fibrotic gene expression, we performed Venn diagram analysis of 
genes upregulated with TGF-β1 at all time points and downregulated with 24 hours of 
JQ1 and TGF-β1 treatment (Figure 4-3C), with false rate discovery >0.001 and log fold 
change >0.58. The analysis identified 26 genes common amongst all 4 datasets and 
suggested that these genes may play a critical role in fibrotic progression, and that early 
repression of these genes may be a key step in mounting an anti-fibrotic response (Table 
4-3). Multiple members of the IL-6 family of cytokines such as IL-6, LIF, and IL-32 as 
well as other pro-inflammatory cytokines such as IL-1A were identified within the subset 
of 26 genes, suggesting that suppression of pro-inflammatory signaling may be a key 
initial anti-fibrotic event. Confirmation by qRT-PCR showed that markers of fibrosis 
(ACTA2, COL1A1) and the subset of inflammatory genes are indeed upregulated with 
TGF-β1 and downregulated with JQ1 treatment (Figure 4-3D). Using quantitative 
ELISA, we further established TGF-β1 induced dose response on secretion of IL-6 that 
was dramatically suppressed with 1uM JQ1 treatment in human primary HSC culture 
media (Figure 4-3E).  
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Table 4-2. 26 genes consistently upregulated with TGF-β1 activation that are 
downregulated within 24 hours of JQ1 treatment in HSC 
Feature Gene Name Description 
ENSG00000229647 AC007879.7 lncRNA 
ENSG00000230838 AC093850.2 lncRNA 
ENSG00000222032 AC112721.2 lncRNA 
ENSG00000049192 ADAMTS6 ADAM metallopeptidase with thrombospondin type 1 motif; 6 
ENSG00000084636 COL16A1 collagen; type XVI; alpha 1 
ENSG00000163739 CXCL1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity; 
alpha) 
ENSG00000163735 CXCL5 chemokine (C-X-C motif) ligand 5 
ENSG00000078098 FAP fibroblast activation protein; alpha 
ENSG00000176971 FIBIN fin bud initiation factor homolog (zebrafish) 
ENSG00000119714 GPR68 G protein-coupled receptor 68 
ENSG00000166923 GREM1 gremlin 1; DAN family BMP antagonist 
ENSG00000170961 HAS2 hyaluronan synthase 2 
ENSG00000163909 HEYL hes-related family bHLH transcription factor with YRPW motif-like 
ENSG00000008517 IL32 interleukin 32 
ENSG00000136244 IL6 interleukin 6 
ENSG00000122641 INHBA inhibin; beta A 
ENSG00000198542 ITGBL1 integrin; beta-like 1 (with EGF-like repeat domains) 
ENSG00000128342 LIF leukemia inhibitory factor 
ENSG00000117122 MFAP2 microfibrillar-associated protein 2 
ENSG00000078114 NEBL Nebulette 
ENSG00000108405 P2RX1 purinergic receptor P2X; ligand gated ion channel; 1 
ENSG00000133110 POSTN periostin; osteoblast specific factor 
ENSG00000017483 SLC38A5 solute carrier family 38; member 5 
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ENSG00000175600 SUGCT succinyl-CoA:glutarate-CoA transferase 
ENSG00000117586 TNFSF4 tumor necrosis factor (ligand) superfamily; member 4 
ENSG00000101255 TRIB3 tribbles pseudokinase 3 
ENSG00000111424 VDR vitamin D (1;25- dihydroxyvitamin D3) receptor 
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In liver injury, IL-6 plays an important role as a key pro-regenerative factor and 
acute phase inducer [143].  IL-6 activates STAT3 pathway in HSCs by interacting with 
both soluble and membrane bound forms of its receptor IL-6RA which then dimerizes 
with membrane bound receptor gp130 to trigger signaling events. Once IL-
6/IL6RA/gp130 complex is formed, STAT3 is phosphorylated by JAK kinases and 
translocated to the nucleus to initiate transcription of its target genes which are mostly 
pro-inflammatory. IL-6 is also a direct target gene of STAT3 which then leads to positive 
feedback in STAT3 activation.  As we had observed significant suppression of IL-6 (Fig 
4-3E), Western blot analysis of HSC treated with TGF-β1 indeed showed increased 
phosphorylation of STAT3 that was markedly reduced by treatment with JQ1 (Fig 4-3F, 
G). Our observation of increased STAT3 phosphorylation from TGF-β1 treatment in 
primary human hepatic stellate cells is in agreement with a recent study that reported 
STAT3 phosphorylation induced by TGF-β1 treatment in lung and dermal fibroblasts of 
systemic sclerosis patients [92, 144].  
STAT3 inhibition impacts human primary HSC derived myofibroblast viability. 
HSC-derived myofibroblasts can be activated and increase type I collagen 
production when the STAT3 pathway is activated [145]. To examine the effect of STAT3 
inhibition on activated primary human HSCs, we evaluated the impact of 
pharmacological inhibition by Cpd188, a reported STAT3 specific inhibitor [146]. 
Cpd188 inhibits STAT3 by targeting the SH2 domain of the peptide binding pocket 
[147]. We confirmed that Cpd188 inhibited IL-6 mediated STAT3 phosphorylation in 
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primary human HSCs by Western blot analysis (Fig 4-4A, B) by administering various 
concentrations of Cpd188 (0.01-81uM) and measuring cell viability, α-SMA expression 
and type I collagen deposition in TGF-β1 activated HSCs by immunofluorescence. In our 
immunofluorescence measurement, we observed numbers of nuclei relative to cells 
treated without Cpd188 were decreasing in a dose dependent manner and consequently 
impacted expression of α-SMA and Collagen I (Figure 4-4C). Importantly, this suggests 
that STAT3 is not only important in activation but also in maintaining cell viability of 
primary human HSC derived myofibroblasts.  
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Figure 4-4. STAT3 inhibition decreases human primary HSC derived myofibroblast 
cell viability.  
A) Western blot analysis of IL6 treated HSCs confirm increased STAT3 phosphorylation 
in HSCs that is inhibited by Cpd188 (9µM). HSC were treated with Cpd188 for 1.5 hours 
and then stimulated with IL-6 for 30 minutes.  B) Bar graph representing densitometry 
from Western blot in Figure 3A, n=3; error bars represent standard error of mean (SEM) 
and graph is a representative from 3 separate experiments.  **** p<0.0001 by ANOVA 
with significance set at p< 0.05. C) Quantitation of number of nuclei, α-SMA and 
collagen I immunofluorescence after 48 hours of TGF-β1 treatment (200pg/ml or 
50pg/ml, respectively) with Cpd188 (0.01-81uM) treatment in HSCs. % α-SMA, 
Collagen I and # of nuclei normalized to value at Cpd188=0 µM treatment. n=3; error 
bars represent standard error of mean (SEM) and graph is a representative from 3 
separate experiments.  
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 STAT3 inhibition in HSC-derived myofibroblasts induces apoptosis, a critical phase in 
fibrotic resolution. 
Clearance of myofibroblasts by apoptosis is a key step in fibrosis reversal [22]. 
STAT3 plays a key role in regulating cell proliferation, cell cycle and apoptosis; direct 
STAT3 transcription targets include Bcl-2 family of proteins, c-Myc and cyclin D1 [148]. 
In the context of hepatic stellate cells, administration of sorafenib or SC-1, inhibitors of a 
critical downstream phosphatase SHP-1 in STAT3 signaling pathway, induce apoptosis 
in primary mouse stellate cells, human hepatic stellate cell line LX-2 and mouse hepatic 
stellate cell line HSC-T6 that can be rescued by overexpression of STAT3 [96]. We 
investigated whether decrease in number of nuclei with increasing concentration of 
Cpd188, a direct STAT3 inhibitor, was similarly due to increased apoptosis and therefore 
setting the early stage for resolution of fibrosis in HSCs in activated primary human 
HSCs. As shown in Fig 4-5A, administration of 9-81µM Cpd188 in HSCs with and 
without 1 µg/ml TGF-β1 activation similarly decreased cell proliferation and viability in 
a dose responsive manner measured by levels of tetrazolium salt (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) 
in culture media following treatment, suggesting STAT3 inhibition impacts viability in 
both activated and non-activated human primary HSCs. At 0uM Cpd188, we did not 
observe a difference in viability between TGF-β1 treated and non-treated HSCs. 
Interestingly, STAT3 was phosphorylated in non-activated human primary HSCs, 
suggesting non- TGF-β1 mediated STAT3 signaling may be important in HSC 
homeostasis (Figure 4-4A). STAT3 is also the transcription factor for myeloid cell 
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leukemia-1 (Mcl-1) in HSCs, an anti-apoptotic factor in the Bcl-2 family of proteins, 
which further supports the importance of STAT3 signaling in HSCs [96]. MTS 
measurement also confirmed that the decrease in number of nuclei measured by 
immunofluorescence was indicative of loss in viability, not increased cell detachment.  
To confirm that Cpd188 mediated STAT3 inhibition is impacting cell viability by 
increasing apoptosis in TGF-β1 activated HSC derived myofibroblasts, we overexpressed 
STAT3 with adenoviral transduction in primary human hepatic stellate cells and 
measured Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) after 
81µM Cpd188 and 1 µg/ml TGF-β1 treatment for 48 hours. Western blot analysis 
confirmed that cells transduced with STAT3 overexpressing adenoviral vector compared 
to cells transduced with control adenoviral vector had increased phosphorylated and total 
STAT3 (Figure 4-5B, C).  As shown in Figure 4-5D, overexpression of STAT3 reduces 
the extent of apoptosis induced by Cpd188 as evidenced by TUNEL stain in TGF-β1 
activated primary human HSCs.   
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Figure 4-5. STAT3 inhibition in primary human HSC decreases proliferation and 
induces apoptosis. 
A) Inhibition of STAT3 by Cpd188 results in decreased proliferation and cell viability in 
TGF-β1   activated and non-activated HSCs as measured by ATP in cell media by MTS 
assay. Error bars represent standard error of mean (SEM), n=3. Percent viability was 
normalized to luminescence at 0 µM Cpd188 treatment B) Western blot analysis 
confirms that cells transduced with adenoSTAT3 results in significant increase in 
phosphorylated and total STAT3 as compared to cells transduced with control adenoviral 
vector. C) Quantitation of western blot densitometry in Figure 4B, n=3; error bars 
represent SEM, significance at p<0.05, * p=0.0495, ** p=0.0064 by Student’s t test. D) 
STAT3 overexpression partially rescues Cpd188 mediated apoptosis in TGF-β1   
activated primary human HSCs, n=3. Error bars represent standard error of mean (SEM), 
data are representative from 3 separate experiments; significance was set at p<0.05, 
**p=0.0080 by Student’s t test. 
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In this study, we used RNA-Seq driven longitudinal transcriptomic study of 
primary human HSC undergoing activation and fibrotic repression and identified STAT3 
pathway as a critical element in TGF-β1-mediated HSC activation and fibrotic repression. 
We demonstrated that pharmacological inhibition of STAT3 pathway impacts viability of 
TGF-β1 activated HSCs by increasing apoptosis, a critical step in resolution of fibrosis. 
Our results suggest that specifically targeting STAT3 pathway inhibition in HSCs may be 
a promising target in development of novel anti-fibrotic therapeutics for hepatic fibrosis 
by promoting apoptosis in hepatic stellate cells, an important source of pathogenic 
myofibroblasts.  
We observed that TGF-β1 mediated activation of HSCs in vitro led to increased 
gene expression of numerous proteins that activate STAT3 pathway, such as IL-6 and 
other cytokines in the IL-6 family. Therefore, rather than targeting individual upstream 
mediators of STAT3 signaling, it may be ideal to target STAT3 directly as a central node 
of the signaling pathway. STAT3 has also been shown to play a critical role as a master 
modulator of TGF-β1 signaling in inflammatory Th17 response in the liver. TGF-β1 
induces development of CD4+ Th17 cells [149, 150] where STAT3 regulated pro-
inflammatory cytokine IL17A induces production of pro-inflammatory and pro-fibrotic 
cytokines in resident macrophage [145]. STAT3 signaling also directly induces 
production of collagen in HSC- derived myofibroblasts which further exacerbates liver 
injury and fibrosis [145]. Inhibition of JAK2, a Janus kinase family tyrosine kinase that 
phosphorylates STAT3, has also been shown to prevent early activation of HSCs [151]. 
Furthermore, JAK1, another JAK kinase family tyrosine kinase was also identified as a 
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direct TGF-β1 receptor I (TGF-β1 RI) interacting protein that activates STAT3 in both 
SMAD independent and dependent pathways that shed a new light on novel JAK-STAT 
pathway activation by TGF-β1 in the liver [95]. Indeed, overexpression of 
phosphorylated STAT3 correlates with fibrotic score in chronic hepatitis B patients with 
advanced liver fibrosis [96] and biopsies from hepatocellular carcinoma, one of the 
possible outcomes of progressive hepatic fibrosis, also stain with high levels of 
phosphorylated STAT3 [152], signifying the importance of STAT3 activation in human 
disease settings. 
STAT3 activation also plays a key role in activation of myofibroblasts in 
pathological fibrosis in multiple organs and diseases. STAT3 deficiency by 
pharmacological inhibition or knock outs in fibroblasts lead to decreased sensitivity to 
TGF-β1 mediated fibrosis ameliorated skin fibrosis in in vitro as well as in vivo mouse 
models of scleroderma (SSc) suggesting that pro-fibrotic signals may converge at STAT3 
as a molecular checkpoint for fibrosis [92]. STAT3 is also essential in regulating type I 
collagen synthesis by COL1A2 enhancer activation in SSc patient derived lung 
fibroblasts [144]. RNAi screening of idiopathic pulmonary fibrosis (IPF) patient derived 
myofibroblasts also identified STAT3 as central to activation and STAT3 inhibition or 
knockdown also attenuated differentiation into myofibroblasts in lung and cardiac 
fibroblasts as well as hepatic stellate cells [98].  These studies, including our own 
approach, suggest an important role of STAT3 in regulation of myofibroblast activation 
in a breadth of fibrotic diseases.  
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 We observed increased apoptosis of HSCs following direct STAT3 inhibition that 
was partially rescued by overexpression of STAT3. Similarly, Su et al. [96] and Gu et 
al.[153] have reported HSC apoptosis following STAT3 inhibition by SHP-1 phosphatase 
or JAK1 kinase inhibition, which further supports that STAT3 inhibition impacts HSC 
viability and apoptosis. However, other factors, such as STAT3 phosphorylation 
independent mechanism may have also led to increased apoptosis observed in our study. 
Additional study to quantitate STAT3 phosphorylation relative to number of apoptotic 
cells may clarify the pathways in which apoptosis occurs in Cpd188 treated HSCs. 
Section Four: Concluding Remarks 
Inhibition of STAT3 signaling could serve as a therapeutic intervention to prevent 
hepatic fibrosis. Phosphorylation of STAT3 by JAK family of tyrosine kinases is a 
critical step in the signaling cascade. Clinically, broad JAK kinase inhibitors such as 
tofacitinib and ruxolitinib have been successfully approved by FDA for treatments in 
inflammatory diseases and cancer. Recent studies have also demonstrated that 
bazedoxifene, a selective estrogen modulator approved for osteoporosis prevention, may 
be a potent gp130 inhibitor that attenuates IL6-gp130-STAT3 pathway and promotes 
apoptosis of malignant cells in models of pancreatic cancer [154]. In addition, 
tocilizumab, a humanized monoclonal antibody targeting IL-6 receptor, has been used 
successfully to treat rheumatoid arthritis, juvenile arthritis and Castleman’s disease [155]. 
This precedence of approved JAK inhibitors and other modulators of STAT3 signaling 
suggest that systemic attenuation of STAT3 pathway may be safe and tolerated in certain 
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patient populations. Currently there are >10 clinical trials for direct STAT3 inhibitors 
(STAT3 SH2 binders and anti-sense oligonucleotides) with target indications in various 
forms of cancer [156]. Our study and others reporting the importance of STAT3 in 
hepatic fibrosis suggest that it may also be an attractive anti-fibrotic target in therapy.  
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CHAPTER FIVE: FINAL THOUGHTS AND FUTURE DIRECTIONS 
Liver fibrosis, specifically, in NAFLD/NASH, is a growing medical concern 
worldwide. Although various risk factors such as metabolic syndromes have been 
identified, mechanisms and pathways that define NAFLD pathogenesis and progression 
are still not well understood. Therefore, novel insights into key drivers involved in 
NAFLD pathogenesis may lead to identification of innovative therapeutics. We 
hypothesized that TSP-1, a protein that has been associated with numerous fibrotic 
diseases, may also play a key role in hepatic fibrosis. In our studies, we demonstrated that 
TSP-1 deficiency attenuates hepatic fibrosis, serum lipid levels and gene expression of 
inflammation markers in a mouse model of NAFLD/NASH. Our transcriptomic analysis 
revealed a previously uncharacterized inverse relationship between PPARα, a well-
known modulator of hepatic lipid metabolism and inflammation, and TSP-1. TSP-1 
inhibition and knockdown in vitro also attenuated HSC activation, a key step in hepatic 
fibrogenesis. 
NAFLD pathogenesis and progression is associated with dysregulation of 
numerous interconnected pathways such as lipid metabolism, inflammation and fibrosis. 
Therefore, treatments targeting all or most of these pathways will likely be necessary to 
demonstrate efficacy. TSP-1 may be an ideal target with its multifaceted roles in fibrosis 
[82, 83, 129], inflammation [157] and lipid metabolism [88] and our study of TSP-1 
knockout mice in CDAHFD model of NASH further supports TSP-1 as a target of 
interest in NAFLD/NASH.  
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There are a few limitations in our study of TSP-1 deficiency in the mouse model 
of NASH by CDAHFD. First, we observed modulation of both mitochondrial 
dysfunction and PPARα pathway that have been implicated as drivers of NAFLD/NASH. 
However, our study did not determine the relationship between these two modulated 
pathways that contribute to attenuation of NAFLD/NASH symptoms. In order to 
extrapolate the individual impact of these two pathways, administration of pathway 
specific modulators, such as PPARα antagonists/agonists, antioxidants and liver specific 
mitochondrial uncouplers, in the CDAHFD model TSP-1 knockout mice may help 
determine the contribution from individual pathways. Second, our study utilized 
CDAHFD which elicits a severe fibrotic phenotype of NASH symptoms in mice. 
However, human NAFLD/NASH patients are not deficient in choline. A follow up study 
with a different model of NASH, such as the Amylin liver NASH (AMLN) model where 
mice are fed ad libitum diet high in fructose, trans-fat and cholesterol, or cross breeding 
genetic models (such as ob/ob leptin deficient or db/db leptin receptor deficient) of 
NASH with TSP-1 knockout mice may provide further insight into the mechanistic view 
of TSP-1 modulation in NASH. Analysis of biopsies from NAFLD/NASH patients 
treated with PPAR agonists to probe modulation of TSP-1 may also provide additional 
clarity and validation for the role of TSP-1 in NAFLD/NASH pathology. Lastly, because 
TSP-1 mediated signaling pathways are complicated and serves numerous functions in a 
context-dependent manner [73], it is difficult to ascertain which TSP-1 interaction 
modulates NAFLD/NASH by knockout studies alone. Therefore, further mechanistic 
studies are necessary to identify how TSP-1 modulates NAFLD/NASH.  
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 We also demonstrated that STAT3 is a pathway of interest in attenuation of 
hepatic stellate cell activation, a key step in hepatic fibrogenesis. We identified STAT3 as 
a pathway of interest using transcriptomic analysis of genes that were consistently 
upregulated in hepatic stellate cells undergoing activation that were also rapidly 
downregulated under anti-fibrotic epigenetic stress. Inhibition of STAT3 led to apoptosis 
in activated HSCs, a key step in resolution of hepatic fibrosis.  A key feature in 
NAFLD/NASH progression is accumulation of fibrosis. Therefore, reduction of fibrosis 
is a key goal in anti-fibrotic therapy and inducing HSC apoptosis via STAT3 inhibition 
may lead to decreased production of scar tissue and fibrotic progression. However, 
additional studies in murine models of NASH may be necessary to determine if STAT3 
inhibition is anti-fibrotic in hepatic fibrosis in vivo to further support our current study 
that examined primary human HSC activation in vitro  
 Currently there are numerous clinical trials on-going to identify treatments against 
NAFLD/NASH. Notable promising agents include PPARα/γ agonist elafibranor, which 
demonstrated resolution of NASH by decreased steatosis, hepatocyte ballooning and 
inflammation without worsening fibrosis in Phase 2 trial, and FXR agonist obeticholic 
acid, which demonstrated improvement in fibrosis without worsening NASH in Phase 2 
trial [39]. Both agents are undergoing Phase 3 trials with estimated completion in 2020-
2022. Furthermore, agents targeting the fibrotic process itself, by inducing apoptosis of 
myofibroblasts, are also undergoing investigation. For example, a clinical trial of siRNA 
targeting heat shock protein 47 (HSP47) to induce apoptosis by promoting collagen 
misfolding within the cell is currently underway for patients with advanced fibrosis of 
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various etiologies [39]. Promising results from such agents may also be relevant in 
treating NAFLD/NASH.  
TSP-1 and STAT3, the targets identified by our studies, encompass similar 
pathways and strategies addressed above in currently on-going trials to address NAFLD. 
Further studies into mechanistic understanding of their role in hepatic fibrosis and/or 
NAFLD pathogenesis may ultimately lead to development of novel therapeutics. 
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